{"SLR NAME":"The effects of ACEIs/ARBs on mortality in COVID-19 infected patients: a meta-analysis and systematic review","References":[{"title1":"Angiotensin?converting enzyme inhibitors or angiotensin II receptor blockers and prognosis of hypertensive patients hospitalised with COVID?19","References":[{"title2":"Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19","References":[{"title3":"A pneumonia outbreak associated with a new coronavirus of probable bat origin"},{"title3":"WHO Coronavirus (COVID-19) Dashboard"},{"title3":"Comorbid chronic diseases and acute organ injuries are strongly correlated with disease severity and mortality among COVID-19 patients: A systemic review and meta-analysis"},{"title3":"Clinical characteristics of coronavirus disease 2019 in China"},{"title3":"Coronavirus disease 2019 case surveillance - United States"},{"title3":"The epidemiological characteristics of an outbreak of 2019 novel Coronavirus diseases (COVID-19) - China"},{"title3":"ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) developed with the special contribution of the Heart Failure Association (HFA) of the ESC"},{"title3":"Hypothesis: Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19"},{"title3":"Extrapulmonary manifestations of COVID-19"},{"title3":"Renin-angiotensin-aldosterone system inhibitors in patients with COVID-19"},{"title3":"Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: Molecular mechanisms and potential therapeutic target"},{"title3":"Preventing a COVID-19 pandemic"},{"title3":"SARS-CoV2: Should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19?"},{"title3":"Hypertension delays viral clearance and exacerbates airway hyperinflammation in patients with COVID-19"},{"title3":"Renin-angiotensin-aldosterone system blockers and the risk of COVID-19"},{"title3":"Renin-angiotensin-aldosterone system inhibitors and risk of COVID-19"},{"title3":"Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China"},{"title3":"Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19"},{"title3":"Association of use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with testing positive for coronavirus disease 2019 (COVID-19)"},{"title3":"Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: A prospective, randomised, open-label trial"},{"title3":"Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): A prospective, parallel group, randomised, controlled, open-label trial"},{"title3":"Effect of discontinuing vs continuing angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on days alive and out of the hospital in patients admitted with COVID-19: A randomized clinical trial"},{"title3":"Effects of renin-angiotensin-aldosterone inhibitors on early outcomes of hypertensive COVID-19 patients: A randomized triple-blind clinical trial"},{"title3":"The use of propensity score methods with survival or time-to-event outcomes: Reporting measures of effect similar to those used in randomized experiments"},{"title3":"Do observational studies using propensity score methods agree with randomized trials? A systematic comparison of studies on acute coronary syndromes"},{"title3":"Comparison of evidence of treatment effects in randomized and nonrandomized studies"},{"title3":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews"},{"title3":"The cochrane collaboration's tool for assessing risk of bias in randomised trials"},{"title3":"Ottawa Hospital Research Institute. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses; 2021. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp."},{"title3":"Measuring inconsistency in meta-analyses"},{"title3":"Chronic use of renin-angiotensin-aldosterone inhibitors in hypertensive COVID-19 patients: Results from a Spanish registry and meta-analysis"},{"title3":"Effects of recent use of renin-angiotensin system inhibitors on mortality of patients with coronavirus disease 2019"},{"title3":"Impact of in-hospital discontinuation with angiotensin receptor blockers or converting enzyme inhibitors on mortality of COVID-19 patients: A retrospective cohort study"},{"title3":"Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans"},{"title3":"Association of hypertension and antihypertensive treatment with COVID-19 mortality: A retrospective observational study"},{"title3":"Effects of renin-angiotensin system blockers on the risk and outcomes of severe acute respiratory syndrome coronavirus 2 infection in patients with hypertension"},{"title3":"The association of COVID-19 occurrence and severity with the use of angiotensin converting enzyme inhibitors or angiotensin-II receptor blockers in patients with hypertension"},{"title3":"Clinical features of COVID-19 in patients with essential hypertension and the impacts of renin-angiotensin-aldosterone system inhibitors on the prognosis of COVID-19 patients"},{"title3":"Effect of renin-angiotensin-aldosterone system inhibitors on Covid-19 patients in Korea"},{"title3":"A retrospective study from 2 centers in China on the effects of continued use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with hypertension and COVID-19"},{"title3":"Impact of renin-angiotensin system inhibitors use on mortality in severe COVID-19 patients with hypertension: A retrospective observational study"},{"title3":"Use of inhibitors of the renin-angiotensin system in hypertensive patients and COVID-19 severity: A systematic review and meta-analysis"},{"title3":"Association between renin-angiotensin-aldosterone system inhibitors and clinical outcomes in patients with COVID-19: A systematic review and meta-analysis"},{"title3":"Associations between the use of renin-angiotensin system inhibitors and the risks of severe COVID-19 and mortality in COVID-19 patients with hypertension: A meta-analysis of observational studies"},{"title3":"Mortality and severity in COVID-19 patients on ACEIs and ARBs - A systematic review, meta-analysis, and meta-regression analysis"},{"title3":"Risks and impact of angiotensin-converting enzyme inhibitors or angiotensin-receptor blockers on SARS-CoV-2 infection in adults: A living systematic review"},{"title3":"Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: Findings from the OPTIMIZE-HF program"}]},{"title2":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?","References":[{"title3":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study"},{"title3":"Clinical characteristics of coronavirus disease 2019 in China"},{"title3":"Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan, China"},{"title3":"Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS"},{"title3":"The vasoprotective axes of the renin-angiotensin system: physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases"}]},{"title2":"Preventing a COVID-19 pandemic: ACE inhibitors as a potential risk factor for fatal COVID-19","References":[]},{"title2":"Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?","References":[{"title3":"Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID- 19 pandemic?"},{"title3":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?"},{"title3":"Does the angiotensin-converting enzyme (ACE)/ACE2 balance contribute to the fate of angiotensin peptides in programmed hypertension?"},{"title3":"Effects of sodium glucose co-transporter 2 inhibitors on the kidney"},{"title3":"Activation of the GLP-1 receptor by liraglutide increases ACE2 expression, reversing right ventricle hypertrophy, and improving the production of SP-A and SP-B in the lungs of type 1 diabetes rats"},{"title3":"Effects of rosuvastatin on expression of angiotensin-converting enzyme 2 after vascular balloon injury in rats"},{"title3":"Angiotensin-converting enzyme 2 (ACE2) is a key modulator of the renin angiotensin system in health and disease"}]},{"title2":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","References":[{"title3":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster"},{"title3":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: adescriptivestudy"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study"},{"title3":"First case of 2019 novel coronavirus in the United States"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"Lung CT image of a confirmed case of the 2019 novel coronavirus (2019-nCoV) infected pneumonia (With differential diagnosis of the SARS)"},{"title3":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia"},{"title3":"Role of neutrophil to lymphocyte and monocyte to lymphocyte ratios in the diagnosis of bacterial infection in patients with fever"},{"title3":"Coronavirus infections-more than just the common cold"},{"title3":"The association between the neutrophil-to-lymphocyte ratio and mortality in critical illness: an observational cohort study"},{"title3":"A new coronavirus associated with human respiratory disease in China"},{"title3":"Monocyte/lymphocyte ratio as a better predictor of cardiovascular and all-cause mortality in hemodialysis patients: a prospective cohort study"},{"title3":"Ratio of neutrophil to lymphocyte counts-rapid and simple parameter of systemic inflammation and stress in critically ill"},{"title3":"Neutrophil-lymphocyte ratio as an early new marker in AIV-H7N9-infected patients: a retrospective study"}]},{"title2":"Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China","References":[]},{"title2":"Coronavirus disease 2019 (COVID-19) and cardiovascular disease: a viewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection","References":[{"title3":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor"},{"title3":"Susceptibility to SARS coronavirus S protein-driven infection correlates with expression of angiotensin converting enzyme 2 and infection can be blocked by soluble receptor"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study"},{"title3":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China"},{"title3":"Clinical characteristics of coronavirus disease 2019 in China"},{"title3":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2"},{"title3":"Effects of spironolactone and eprosartan on cardiac remodeling and angiotensin-converting enzyme isoforms in rats with experimental heart failure"},{"title3":"Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors"},{"title3":"Expert recommendations for management and treatment of cardiovascular diseases under the epidemic situation of novel coronavirus pneumonia in Hubei province"},{"title3":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury"},{"title3":"Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury"},{"title3":"The ACE2/angiotensin-(1-7)/MAS axis of the renin-angiotensin system: focus on angiotensin-(1-7)"},{"title3":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia"},{"title3":"Age-dependent differences in pulmonary host responses in ARDS: a prospective observational cohort study"},{"title3":"Initial viral load and the outcomes of SARS"},{"title3":"Recombinant human ACE2: acing out angiotensin II in ARDS therapy"},{"title3":"A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome"},{"title3":"SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS"},{"title3":"Histological findings of COVID-19 based on autopsy: a case report"},{"title3":"Potent neutralization of 2019 novel coronavirus by recombinant ACE2-Ig"}]},{"title2":"Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy","References":[]},{"title2":"Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19","References":[]},{"title2":"Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China","References":[]},{"title2":"Effects of ARBs and ACEIs on virus infection, inflammatory status and clinical outcomes in COVID-19 patients with hypertension: a single center retrospective study","References":[]},{"title2":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","References":[{"title3":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor"},{"title3":"Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2"},{"title3":"A pneumonia outbreak associated with a new coronavirus of probable bat origin"},{"title3":"Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19"},{"title3":"Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors"},{"title3":"Relationship between angiotensin-converting enzyme insertion/deletion gene polymorphism and prostate cancer susceptibility"},{"title3":"Cell entry mechanisms of SARS-CoV-2"},{"title3":"Tissue ACE phenotyping in prostate cancer"},{"title3":"Effects of the angiotensin-I-converting enzyme inhibitor perindopril on tumor growth and angiogenesis in head and neck squamous cell carcinoma cells"},{"title3":"Clinical characteristics and results of semen tests among men with coronavirus disease 2019"},{"title3":"Role of proprotein convertases in prostate cancer progression"},{"title3":"Expression of ACE2, the SARS-CoV-2 receptor, and TMPRSS2 in prostate epithelial cells"},{"title3":"Inflammation-induced oxidative stress mediates gene fusion formation in prostate cancer"},{"title3":"Androgens and androgen receptor signaling in prostate tumorigenesis"},{"title3":"Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2"},{"title3":"The trinity of COVID-19: immunity, inflammation and intervention"},{"title3":"Epigenetic impact of infection on carcinogenesis: mechanisms and applications"},{"title3":"Prostate cancer and inflammation: the evidence"}]},{"title2":"Coronavirus disease 2019 (COVID-19): do angiotensin-converting enzyme inhibitors/angiotensin receptor blockers have a biphasic effect?","References":[{"title3":"A novel coronavirus from patients with pneumonia in China, 2019"},{"title3":"An interactive web-based dashboard to track COVID-19 in real time"},{"title3":"The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19):China, 2020"},{"title3":"Angiotensin-converting enzyme inhibitors in hypertension: to use or not to use?"},{"title3":"The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells"},{"title3":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2"},{"title3":"Rapid response: re: preventing a covid-19 pandemic: ACE inhibitors as a potential risk factor for fatal Covid-19"},{"title3":"HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19"},{"title3":"Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study"},{"title3":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China"},{"title3":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study"},{"title3":"Estimation of risk factors for COVID-19 mortality:preliminary results"},{"title3":"Trends in antihypertensive medication monotherapy and combination use among US adults, National Health and Nutrition Examination Survey 2005-2016"},{"title3":"Case definition and European surveillance for COVID-19, as of 2 March 2020"},{"title3":"Coronavirus disease 2019 and cardiovascular disease: a viewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection"},{"title3":"Sex differences in the aging pattern of renin-angiotensin system serum peptidases"},{"title3":"Angiotensin converting enzyme 2 activity and human atrial fibrillation: increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural remodelling"},{"title3":"ACE and ACE2: their role to balance the expression of angiotensin II and angiotensin-(1-7)"},{"title3":"The ANG-(1-7)/ACE2/mas axis in the regulation of nephron function"},{"title3":"Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats"},{"title3":"Human intestine luminal ACE2 and amino acid transporter expression increased by ACE-inhibitors"},{"title3":"New perspectives in the renin-angiotensin-aldosterone system (RAAS) IV: circulating ACE2 as a biomarker of systolic dysfunction in human hypertension and heart failure"},{"title3":"Circulating ACE2 activity correlates with cardiovascular disease development"},{"title3":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury"},{"title3":"Angiotensin-converting enzyme 2 inhibits lung injury induced by respiratory syncytial virus"}]},{"title2":"COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. What is the evidence?","References":[{"title3":"Trends in antihypertensive medication monotherapy and combination use among US adults, National Health and Nutrition Examination Survey 2005-2016"},{"title3":"Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19"},{"title3":"Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019:COVID-NET, 14 States, March 1-30, 2020"},{"title3":"Risk factors for hospitalization, mechanical ventilation, or death among 10 131 US veterans with SARS-CoV-2 infection"},{"title3":"Drugs and the renin-angiotensin system in covid-19"},{"title3":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?"},{"title3":"Renin-angiotensin-aldosterone system inhibitors and COVID-19 infection or hospitalization: a cohort study"},{"title3":"Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy"},{"title3":"Renin-angiotensin-aldosterone system blockers and the risk of Covid-19"},{"title3":"Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study"},{"title3":"Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality"},{"title3":"Coronavirus disease 2019 and hypertension: the role of angiotensin-converting enzyme 2 and the renin-angiotensin system"},{"title3":"Good ACE, bad ACE do battle in lung injury, SARS"},{"title3":"Kidney and lung ACE2 expression after an ACE inhibitor or an Ang II receptor blocker: implications for COVID-19"},{"title3":"Clinical and proteomic correlates of plasma ACE2 (angiotensin-converting enzyme 2) in human heart failure"},{"title3":"The expanding role of real-world evidence trials in health care decision making"},{"title3":"Real world evidence (RWE):are we (RWE) ready?"}]},{"title2":"Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19","References":[]},{"title2":"SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19?","References":[]},{"title2":"Hypertension and COVID-19","References":[]},{"title2":"Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19","References":[]},{"title2":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2","References":[]},{"title2":"Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker","References":[]},{"title2":"The ANG-(1-7)/ACE2/mas axis in the regulation of nephron function","References":[]},{"title2":"Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats","References":[]},{"title2":"Coronavirus disease 2019 (COVID-19) infection and renin angiotensin system blockers","References":[]},{"title2":"Renin-angiotensin-aldosterone system blockers and the risk of Covid-19","References":[{"title3":"Physiology of local renin-angiotensin systems."},{"title3":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus."},{"title3":"A pneumonia outbreak associated with a new coronavirus of probable bat origin."},{"title3":"Pharmacologic modulation of ACE2 expression."},{"title3":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2."},{"title3":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?"},{"title3":"Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic?"},{"title3":"Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19."},{"title3":"Renin-angiotensin system blockers and the COVID-19 pandemic."},{"title3":"Angiotensin-converting enzyme inhibitor/angiotensin II receptor blockers and pneumonia risk among stroke patients."},{"title3":"Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China."},{"title3":"Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)."},{"title3":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study."},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study."},{"title3":"Clinical characteristics of coronavirus disease 2019 in China."},{"title3":"SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19?"},{"title3":"HFSA/ACC/AHA statement addresses concerns re: using RAAS antagonists in COVID-19"},{"title3":"COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what is the evidence?"},{"title3":"Hypertension, the renin-angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19."},{"title3":"Risks associated with permanent discontinuation of blood pressure-lowering medications in patients with type 2 diabetes."},{"title3":"Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial."},{"title3":"Incidence, predictors, and outcomes associated with hypotensive episodes among heart failure patients receiving sacubitril/valsartan or enalapril: the PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure)."},{"title3":"Coronavirus emergency."},{"title3":"Early cardiovascular protection by initial two-drug fixed-dose combination treatment vs. monotherapy in hypertension."},{"title3":"Generating evidence from computerized healthcare utilization databases."},{"title3":"Adherence with antihypertensive drug therapy and the risk of heart failure in clinical practice."},{"title3":"Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR."},{"title3":"A new population-based risk stratification tool was developed and validated for predicting mortality, hospital admissions, and health care costs."},{"title3":"Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy."}]},{"title2":"Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study","References":[{"title3":"Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS coronavirus"},{"title3":"The vasoprotective axes of the renin-angiotensin system: physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases"},{"title3":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2"},{"title3":"Enalapril attenuates downregulation of angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rats"},{"title3":"Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan"},{"title3":"Could ACE inhibitors and particularly ARBs increase susceptibility to COVID-19 infection?"},{"title3":"Preventing a covid-19 pandemic"},{"title3":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?"},{"title3":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study"},{"title3":"Clinical characteristics of coronavirus disease 2019 in China"},{"title3":"Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan, China"},{"title3":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study"},{"title3":"Angiotensin receptor blockers as tentative SARS-COV-2 therapeutics"},{"title3":"Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19"},{"title3":"Active surveillance of severe cutaneous adverse reactions: a case-population approach using a registry and a health care database"},{"title3":"Interaction revisited: the difference between two estimates"},{"title3":"Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients"},{"title3":"Coronavirus disease 2019 (COVID-19) and cardiovascular disease: a viewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection"},{"title3":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury"},{"title3":"Age- and gender-related difference of ACE2 expression in rat lung"},{"title3":"Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19"},{"title3":"Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury"},{"title3":"Circulating angiotensin peptides levels in acute respiratory distress syndrome correlate with clinical outcomes: a pilot study"},{"title3":"Angiotensin-converting enzyme 2 protects from severe acute lung failure"},{"title3":"Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections"},{"title3":"Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury"},{"title3":"Coronavirus disease 2019 (COVID-19): do angiotensin-converting enzyme inhibitors/angiotensin receptor blockers have a biphasic effect?"},{"title3":"Treatment with ACE-inhibitors is associated with less severe disease with SARS-Covid-19 infection in a multi-site UK acute hospital trust"},{"title3":"Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China"},{"title3":"Assessment and control for confounding by indication in observational studies"},{"title3":"Diabetes as a risk factor for the progression and prognosis of COVID-19"},{"title3":"Characterization of ACE and ACE2 expression within different organs of the NOD mouse"}]},{"title2":"  . Position statement of the ESC Council on Hypertension on ACE-inhibitors and angiotensin receptor blockers [cited 2020 Mar 13]. Available from URL: https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang ","References":[]},{"title2":"The national early warning score 2 (NEWS2)","References":[{"title3":"Annual Epidemiological Surveillance Report 2019"},{"title3":"Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the american thoracic society and infectious diseases society of America"},{"title3":"Association between timing of intensive care unit admission and outcomes for emergency department patients with community-acquired pneumonia"},{"title3":"Validity of Pneumonia Severity Assessment Scores in Africa and South Asia: A Systematic Review and Meta-Analysis"},{"title3":"Prediction of severe community-acquired pneumonia: A systematic review and meta-analysis"},{"title3":"Severity assessment tools to guide ICU admission in community-acquired pneumonia: Systematic review and meta-analysis"},{"title3":"Infectious Diseases Society of America/American Thoracic Society Consensus Guidelines on the Management of Community-Acquired Pneumonia in Adults"},{"title3":"Validation of the Infectious Disease Society of America/American Thoracic Society 2007 guidelines for severe community-acquired pneumonia"},{"title3":"Validation of the Infectious Diseases Society of America/American Thoratic Society Minor Criteria for Intensive Care Unit Admission in Community-Acquired Pneumonia Patients without Major Criteria or Contraindications to Intensive Care Unit Care"},{"title3":"Validation and clinical implications of the IDSA/ATS minor criteria for severe community-acquired pneumonia"},{"title3":"Modified IDSA/ATS Minor Criteria for Severe Community-Acquired Pneumonia Best Predicted Mortality"},{"title3":"Simplification of the IDSA/ATS criteria for severe CAP using meta-analysis and observational data"},{"title3":"NEWSDIG: The National Early Warning Score Development and Implementation Group"},{"title3":"The National Early Warning Score 2 (NEWS2)"},{"title3":"The National Early Warning Score (NEWS) for outcome prediction in emergency department patients with community-acquired pneumonia: Results from a 6-year prospective cohort study"},{"title3":"Effect of hypoproteinemia on the mortality of sepsis patients in the ICU: A retrospective cohort study"},{"title3":"Predictors of early progression to severe sepsis or shock among emergency department patients with nonsevere sepsis"},{"title3":"Blood Urea Nitrogen (BUN) is independently associated with mortality in critically ill patients admitted to ICU"},{"title3":"Blood urea nitrogen (BUN) independently predicts mortality in critically ill patients admitted to ICU: A multicenter study"},{"title3":"Elevation of blood urea nitrogen is predictive of long-term mortality in critically ill patients independent of &quot;normal&quot; creatinine"},{"title3":"Analysis of the Value of the Blood Urea Nitrogen to Albumin Ratio as a Predictor of Mortality in Patients with Sepsis"},{"title3":"Urea to albumin ratio is a predictor of mortality in patients with septic shock"},{"title3":"Association between blood urea nitrogen to serum albumin ratio and in-hospital mortality of patients with sepsis in intensive care: A retrospective analysis of the fourth-generation Medical Information Mart for Intensive Care database"}]},{"title2":"National early warning score (NEWS) 2: standardising the assessment of acute-illness severity in the NHS","References":[]},{"title2":"Vademecum for the treatment of people with COVID-19. Edition 2.0, 13 March 2020","References":[]},{"title2":"An interactive web-based dashboard to track COVID-19 in real time","References":[{"title3":"WHO statement regarding cluster of pneumonia cases in Wuhan, China"},{"title3":"Coronavirus disease 2019 (COVID-19) situation reports"},{"title3":"Tracking the epidemic"}]},{"title2":"Clinical characteristics of coronavirus disease 2019 in China","References":[{"title3":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia."},{"title3":"Challenges in laboratory diagnosis of the novel coronavirus SARS-CoV-2."},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China."},{"title3":"First case of 2019 novel Coronavirus in the United States."},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study."},{"title3":"A novel coronavirus associated with severe acute respiratory syndrome."},{"title3":"A preventive and control strategy for COVID-19 infection: an experience from a Third-Tier Chinese City."},{"title3":"An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies."},{"title3":"Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China."},{"title3":"Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2."},{"title3":"COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics."},{"title3":"Transplantation of ACE2(-) mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia."},{"title3":"On the use of corticosteroids for 2019-nCoV pneumonia."},{"title3":"Comprehensive analysis of drugs to treat SARSCoV2 infection: mechanistic insights into current COVID19 therapies (Review)."},{"title3":"The role of telemedicine during the COVID-19 epidemic in China-experience from Shandong province."},{"title3":"Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial."},{"title3":"Intravenous infusion of human umbilical cord Wharton's jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia."},{"title3":"Flattening the COVID-19 curve with natural killer cell based immunotherapies."},{"title3":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster."},{"title3":"Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event."},{"title3":"Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside Wuhan, China."},{"title3":"Spatio-temporal metabolokinetics and efficacy of human placenta-derived mesenchymal stem/stromal cells on mice with refractory Crohn's-like enterocutaneous fistula."},{"title3":"High-efficient generation of VCAM-1(+) mesenchymal stem cells with multidimensional superiorities in signatures and efficacy on aplastic anaemia mice."},{"title3":"Systematic comparison of hUC-MSCs at various passages reveals the variations of signatures and therapeutic effect on acute graft-versus-host disease."},{"title3":"JNKi- and DAC-programmed mesenchymal stem/stromal cells from hESCs facilitate hematopoiesis and alleviate hind limb ischemia."},{"title3":"Identification of a novel coronavirus in patients with severe acute respiratory syndrome."},{"title3":"Studies on viral pneumonia related to novel coronavirus SARS-CoV-2, SARS-CoV, and MERS-CoV: a literature review."},{"title3":"Three emerging coronaviruses in two decades."},{"title3":"The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future."},{"title3":"Coronaviruses - drug discovery and therapeutic options."},{"title3":"The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice."},{"title3":"Acute respiratory distress syndrome: the Berlin Definition."},{"title3":"Pediatric acute respiratory distress syndrome: definition, incidence, and epidemiology: proceedings from the Pediatric Acute Lung Injury Consensus Conference."},{"title3":"Eicosanoid storm in infection and inflammation."},{"title3":"Decoding the enigma of antiviral crisis: does one target molecule regulate all?"}]},{"title2":"Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis","References":[]},{"title2":"Comparative effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers on the risk of pneumonia and severe exacerbations in patients with COPD","References":[{"title3":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010"},{"title3":"Projections of global mortality and burden of disease from 2002 to 2030"},{"title3":"Chronic obstructive pulmonary disease and risk of infection"},{"title3":"Pulmonary infection control window as a switching point for sequential ventilation in the treatment of COPD patients: a meta-analysis"},{"title3":"Severe exacerbation and pneumonia in COPD patients treated with fixed combinations of inhaled corticosteroid and long-acting beta2 agonist"},{"title3":"Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease"},{"title3":"The association between inhaled corticosteroid and pneumonia in COPD patients: the improvement of patients' life quality with COPD in Taiwan (IMPACT) study"},{"title3":"Should patients with COPD be vaccinated?"},{"title3":"The association of renin-angiotensin system blockades and pneumonia requiring admission in patients with COPD"},{"title3":"Angiotensin receptor subtype AT(1) mediates alveolar epithelial cell apoptosis in response to ANG II"},{"title3":"Angiotensin II type 1 receptor blocker inhibits pulmonary injury"},{"title3":"Pneumonia risk and use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers"},{"title3":"Antihypertensive agents acting on the renin-angiotensin system and the risk of sepsis"},{"title3":"Association between exposure to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers prior to septic shock and acute kidney injury"},{"title3":"Population-based study of statins, angiotensin II receptor blockers, and angiotensin-converting enzyme inhibitors on pneumonia-related outcomes"},{"title3":"The association of cardioprotective medications with pneumonia-related outcomes"},{"title3":"Risk of pneumonia in patients with gastroesophageal reflux disease: a population-based cohort study"},{"title3":"Reduction of bleomycin induced lung fibrosis by candesartan cilexetil, an angiotensin II type 1 receptor antagonist"},{"title3":"Differential renal effects of candesartan at high and ultra-high doses in diabetic mice-potential role of the ACE2/AT2R/Mas axis"},{"title3":"Angiotensin receptor 1 blockade reduces secretion of inflammation associated cytokines from cultured human carotid atheroma and vascular cells in association with reduced extracellular signal regulated kinase expression and activation"}]},{"title2":"Severity and mortality associated with COPD and smoking in patients with COVID-19: a rapid systematic review and meta-analysis","References":[{"title3":"WHO. Coronavirus disease (COVID-2019) Situation Report 2020 [Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/events-as-they-happen."},{"title3":"WHO. Situation Report -22 2020 [Available from: https://www.who.int/docs/default-source/coronaviruse/situation-reports/20200211-sitrep-22-ncov.pdf?sfvrsn=fb6d49b1_2."},{"title3":"Epidemiology, Genetic Recombination, and Pathogenesis of Coronaviruses"},{"title3":"A Novel Coronavirus from Patients with Pneumonia in China, 2019"},{"title3":"The SARS, MERS and novel coronavirus (COVID-19) epidemics, the newest and biggest global health threats: what lessons have we learned?"},{"title3":"Clinical analysis of 10 neonates born to mothers with 2019-nCoV pneumonia"},{"title3":"GOLD. [Available from: https://goldcopd.org/wp-content/uploads/2019/11/GOLD-2020-REPORT-ver1.0wms.pdf."},{"title3":"Organization WH. Chronic obstructive pulmonary disease (COPD) 2020 [Available from: https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)"},{"title3":"Support System for Early Diagnosis of Chronic Obstructive Pulmonary Disease Based on the Service-Oriented Architecture Paradigm and Business Process Management Strategy: Development and Usability Survey Among Patients and Health Care Providers"},{"title3":"Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of life and daily life activities"},{"title3":"Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease"},{"title3":"Chronic obstructive pulmonary disease. 6: The aetiology of exacerbations of chronic obstructive pulmonary disease"},{"title3":"Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations"},{"title3":"COPD exacerbations: defining their cause and prevention"},{"title3":"Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement"},{"title3":"GA Wells BS, D O'Connell, J Peterson, V Welch, M Losos, P Tugwell. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [cited 2019 23/01]. Available from: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp"},{"title3":"Characteristics and Outcomes of 21 Critically Ill Patients With COVID-19 in Washington State"},{"title3":"Clinical Characteristics of Coronavirus Disease 2019 in China"},{"title3":"Clinical characteristics of laboratory confirmed positive cases of SARS-CoV-2 infection in Wuhan, China: A retrospective single center analysis"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province"},{"title3":"Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China"},{"title3":"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China"},{"title3":"Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China"},{"title3":"Chest CT Findings in Patients with Corona Virus Disease 2019 and its Relationship with Clinical Features"},{"title3":"Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2"},{"title3":"Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series"},{"title3":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study"},{"title3":"Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan"},{"title3":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study"},{"title3":"Initial clinical features of suspected Coronavirus Disease 2019 in two emergency departments outside of Hubei, China"},{"title3":"COVID-19 and smoking: A systematic review of the evidence"},{"title3":"Chronic obstructive pulmonary disease in China: a nationwide prevalence study"},{"title3":"Global burden of COPD: systematic review and meta-analysis"},{"title3":"Comorbidity and its impact on 1,590 patients with COVID-19 in China: A Nationwide Analysis"},{"title3":"Clinical features and outcomes of 221 patients with COVID-19 in Wuhan, China"},{"title3":"Time course and pattern of COPD exacerbation onset"},{"title3":"Impact of radiologically stratified exacerbations: insights into pneumonia aetiology in COPD"},{"title3":"Chronic obstructive pulmonary disease (COPD) exacerbation: impact of comorbidities on length and costs during hospitalization"},{"title3":"Understanding the impact of chronic obstructive pulmonary disease exacerbations on patient health and quality of life"},{"title3":"Nutritional supplementation during pulmonary rehabilitation in COPD: A systematic review"},{"title3":"Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis"},{"title3":"Clinical, laboratory and imaging features of COVID-19: A systematic review and meta-analysis"},{"title3":"Clinical characteristics of 82 death cases with COVID-19"},{"title3":"Clinical characteristics of 101 non-surviving hospitalized patients with COVID-19: A single center, retrospective study"},{"title3":"Clinical characteristics of 36 non-survivors with COVID-19 in Wuhan, China"},{"title3":"Clinical characteristics of 25 death cases infected with COVID-19 pneumonia: a retrospective review of medical records in a single medical center, Wuhan, China"},{"title3":"Mortality in COPD: role of comorbidities"},{"title3":"Critical Care Utilization for the COVID-19 Outbreak in Lombardy, Italy: Early Experience and Forecast During an Emergency Response"},{"title3":"On the front lines of coronavirus: the Italian response to covid-19"},{"title3":"Facing Covid-19 in Italy:Ethics, Logistics, and Therapeutics on the Epidemic's Front Line"},{"title3":"Trends in smoking prevalence and implication for chronic diseases in China: serial national cross-sectional surveys from 2003 to 2013"},{"title3":"Cigarette smoke alters respiratory syncytial virus-induced apoptosis and replication"},{"title3":"Sex difference and smoking predisposition in patients with COVID-19"},{"title3":"Virtually Perfect? Telemedicine for Covid-19"},{"title3":"Global use, utility, and methods of tele-health in COPD: a health care provider survey"}]},{"title2":"Age and multimorbidity predict death among COVID-19 patients: results of the SARS-RAS study of the Italian Society of Hypertension","References":[]},{"title2":"Clinical characteristics and prognostic factors in COVID-19 patients aged &gt;=80 years","References":[{"title3":"The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health:The latest 2019 novel coronavirus outbreak in Wuhan, China"},{"title3":"Coronavirus disease (COVID-19)-World Health Organization. [cited 16 Nov 2020]. Available: https://www.who.int/emergencies/diseases/novel-coronavirus-2019"},{"title3":"COVID-19 ITALIA:Desktop. [cited 16 Nov 2020]. Available: http://opendatadpc.maps.arcgis.com/apps/opsdashboard/index.html#/b0c68bce2cce478eaac82fe38d4138b1"},{"title3":"Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention"},{"title3":"Epidemiology of COVID-19: A systematic review and meta-analysis of clinical characteristics, risk factors, and outcomes"},{"title3":"Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up"},{"title3":"Clinical characteristics and prognostic factors in COVID-19 patients aged &gt;=80 years"},{"title3":"Coronavirus Disease 2019 Case Surveillance:United States, January 22-May 30, 2020"},{"title3":"Severe COVID-19 in the young and healthy: monogenic inborn errors of immunity?"},{"title3":"Clinical features of COVID-19 in elderly patients: A comparison with young and middle-aged patients"},{"title3":"Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases"},{"title3":"REDCap: web-based software for all types of data storage and collection"},{"title3":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation"},{"title3":"Clinical management of severe acute respiratory infection when novel coronavirus (2019-nCoV) infection is suspected Interim guidance 28 January 2020"},{"title3":"Risk factors of critical &amp; mortal COVID-19 cases: A systematic literature review and meta-analysis"},{"title3":"The Impact of COVID-19 Disease on Platelets and Coagulation"},{"title3":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study"},{"title3":"Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors"},{"title3":"Cardiovascular disease as a biomarker for an increased risk of COVID-19 infection and related poor prognosis"},{"title3":"Clinical Characteristics of Coronavirus Disease 2019 in China"},{"title3":"Prediction for Progression Risk in Patients With COVID-19 Pneumonia: The CALL Score"},{"title3":"Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis"},{"title3":"Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019 (COVID-19): a meta-analysis"},{"title3":"Mild versus severe COVID-19: Laboratory markers"},{"title3":"C-reactive protein, procalcitonin, D-dimer, and ferritin in severe coronavirus disease-2019: a meta-analysis"},{"title3":"Comparative analysis of laboratory indexes of severe and non-severe patients infected with COVID-19"},{"title3":"Electrolyte imbalances in patients with severe coronavirus disease 2019 (COVID-19)"},{"title3":"Prevalence of underlying diseases in died cases of COVID-19: A systematic review and meta-analysis"},{"title3":"Metabolic risk factors and risk of Covid-19: A systematic review and meta-analysis"}]},{"title2":"Recommendations for the admission of patients with COVID-19 to intensive care and intermediate care units (ICUs and IMCUs)","References":[]},{"title2":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China","References":[]},{"title2":"Rapid response systems","References":[{"title3":"Failure to rescue: using rapid response systems to improve care of the deteriorating patient in hospital"},{"title3":"&quot;Identifying the hospitalised patient in crisis&quot;--a consensus conference on the afferent limb of rapid response systems"},{"title3":"Findings of the first consensus conference on medical emergency teams*"},{"title3":"Quality metrics for the evaluation of rapid response systems"},{"title3":"Selecting indicators for patient safety at the health systems level in OECD countries heal"},{"title3":"The economics of patient safety"},{"title3":"Economic evaluation in patient safety: a literature review of methods"},{"title3":"Economic impact of medication error: a systematic review"},{"title3":"How hospitals kill our loved ones and conceal it"},{"title3":"Do we really value identified lives more highly than statistical lives?"},{"title3":"Rapid review guidebook steps for conducting a rapid review"},{"title3":"Roundtable on public policy affecting patient safety"},{"title3":"Building capacity for quality and safety in critical care: a roundtable discussion from the second International patient safety conference in April 9-11, 2013, Riyadh, Saudi Arabia"},{"title3":"Designing a patient safety undergraduate medical curriculum: the telluride interdisciplinary roundtable experience"},{"title3":"ICHOM | healthcare improvement | patient-reported outcomes"},{"title3":"Home | nightingale"},{"title3":"Projecting critical care beyond the ICU: an analysis of tele-ICU support for rapid response teams"},{"title3":"Reducing mortality and avoiding preventable ICU utilization: analysis of a successful rapid response program using APR DRGs"},{"title3":"Cost-Benefit analysis of a medical emergency team in a children's Hospital"},{"title3":"Who benefits from aggressive rapid response system treatments near the end of life? a retrospective cohort study"},{"title3":"Regular in-situ simulation training of paediatric medical emergency team leads to sustained improvements in hospital response to deteriorating patients, improved outcomes in intensive care and financial savings"},{"title3":"Financial consequences of the implementation of a rapid response system on a surgical ward"},{"title3":"Apache II: a severity of disease classification system"},{"title3":"Implementing A rapid response system in A tertiary-care hospital. A cost-effectiveness study"},{"title3":"Understanding the economic impact of an essential service: applying time-driven activity-based costing to the hospital airway response team"},{"title3":"Researching COVID-19 tracing app acceptance: incorporating theory from the technological acceptance model"},{"title3":"A real-time wearable system for monitoring vital signs of COVID-19 patients in a hospital setting"},{"title3":"Can continuous remote vital sign monitoring reduce the number of room visits to patients suspected of COVID-19: A quasi-experimental study"},{"title3":"Use of home pulse oximetry with daily short message service messages for monitoring outpatients with COVID-19: the patient's experience"},{"title3":"Remote hospital care for recovering covid-19 patients using telemedicine: a randomised controlled trial"},{"title3":"Telehealth at scale can improve chronic disease management in the community during a pandemic: an experience at the time of COVID-19"},{"title3":"How NICE measures value for mone how NICE measures value for money in relation y in relation to public health interv to public health interventions entions local government briefing"},{"title3":"Introduction to health technology evaluation | NICE health technology evaluations: the manual | guidance | NICE"},{"title3":"Inclusion of carer health-related quality of life in national institute for health and care excellence appraisals"},{"title3":"Good technologies gone bad: how and why the cost-effectiveness of a medical intervention changes for different populations"},{"title3":"The value of heterogeneity for cost-effectiveness subgroup analysis: conceptual framework and application"},{"title3":"TRUST: the 5 rights of the second victim"},{"title3":"Health care professionals as second victims after adverse events: A systematic review"},{"title3":"What really matters? A mixed methods study of treatment preferences and priorities among people with epilepsy in the UK"},{"title3":"Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L)"},{"title3":"Challenges for economic evaluation of health care strategies to contain antimicrobial resistance"},{"title3":"Cost-Effectiveness analysis of the use of point-of-care C-reactive protein testing to reduce antibiotic prescribing in primary care"},{"title3":"Adverse drug reactions in hospital in-patients: A prospective analysis of 3695 patient-episodes"},{"title3":"The economic burden of preventable adverse drug reactions: a systematic review of observational studies"},{"title3":"Cost-effectiveness of screening for HLA-A*31:01 prior to initiation of carbamazepine in epilepsy"},{"title3":"Cost effectiveness analysis of HLA-B*58:01 genotyping prior to initiation of allopurinol for gout"},{"title3":"Cost effectiveness of a pharmacist-led information technology intervention for reducing rates of clinically important errors in medicines management in general practices (pincer)"},{"title3":"Impact of electronic health records on predefined safety outcomes in patients admitted to hospital: a scoping review"},{"title3":"Systematic review of economic analyses in patient safety: a protocol designed to measure development in the scope and quality of evidence"},{"title3":"Improving patient safety: an economic perspective on the role of nurses"},{"title3":"What is value in health care?"},{"title3":"Market failure in health care"},{"title3":"What do we know about financial returns on investments in patient safety? A literature review"},{"title3":"Relationship between occurrence of surgical complications and hospital finances"},{"title3":"The business case for quality: case studies and an analysis"},{"title3":"Time-driven activity-based costing"},{"title3":"Time-driven activity-based costing in health care: a systematic review of the literature"},{"title3":"Correction: checklists for complications during systemic cancer treatment shared by patients, friends, and health care professionals: prospective interventional cohort study"},{"title3":"Embracing change: learnings from implementing multidimensional digital remote monitoring in oncology patients at a district general Hospital during the COVID-19 pandemic"},{"title3":"Use of telemedicine to screen patients in the emergency department: matched cohort study evaluating efficiency and patient safety of telemedicine"},{"title3":"The abrupt expansion of ambulatory telemedicine: implications for patient safety"},{"title3":"Toward a better understanding of the intention to use mHealth apps: exploratory study"},{"title3":"Incidence, duration and cost of futile treatment in end-of-life hospital admissions to three australian public-sector tertiary hospitals: A retrospective multicentre cohort study"},{"title3":"The economics of dying. the illusion of cost savings at the end of life"}]},{"title2":"In-hospital cardiac arrest: incidence, prognosis and possible measures to improve survival","References":[]},{"title2":"Prognostic value of early warning scores in the emergency department (ED) and acute medical unit (AMU): a narrative review","References":[]},{"title2":"National Early Warning Score 2 (NEWS2) on admission predicts severe disease and in-hospital mortality from Covid-19 - a prospective cohort study","References":[{"title3":"European Centre for Disease Prevention and Control - An agency of the European Union webpage: https://www.ecdc.europa.eu/en accessed 27 Apr 2020."},{"title3":"Coronavirus disease 2019 (COVID-19) in the EU/EEA and the UK - ninth update, 23 April 2020 [Report]. Stockholm, 2020: European Centre for Disease Prevention and Control; 2020 [Available from: https://www.ecdc.europa.eu/sites/default/files/documents/covid-19-rapid-risk-assessment-coronavirus-disease-2019-ninth-update-23-april-2020.pdf."},{"title3":"Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020. 10.1001/jama.2020.6775."},{"title3":"Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020. 10.1001/jama.2020.2648."},{"title3":"Prediction models for diagnosis and prognosis in Covid-19"},{"title3":"Ihle-Hansen H, Berge T, Tveita A, Erno PE, Andersen EL, Wang CH, et al. COVID-19: symptoms, course of illness and use of clinical scoring systems for the first 42 patients admitted to a Norwegian local hospital. Tidsskr Nor Legeforen. 2020. 10.4045/tidsskr.20.0301."},{"title3":"Corman VM, Landt O, Kaiser M, Molenkamp R, Meijer A, Chu DK, et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro Surveill. 2020;25(3). 10.2807/1560-7917.Es.2020.25.3.2000045."},{"title3":"Physicians RCo. National Early Warning Score (NEWS) 2: Standardising the assessment of acute-illness severity in the NHS. Updated report of a working party. London: RCP, 20172017 [Available from: https://www.rcplondon.ac.uk/projects/outputs/national-early-warning-score-news-2 accessed 24 Apr 2020."},{"title3":"Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8). 10.1001/jama.2016.0287."},{"title3":"American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Critical care med. 1992;20(6):864-74."},{"title3":"Lim WS, van der Eerden MM, Laing R, Boersma WG, Karalus N, Town GI, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003;58(5). 10.1136/thorax.58.5.377."},{"title3":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5). 10.1016/0021-9681(87)90171-8."},{"title3":"Rockwood K, Song X, MacKnight C, Bergman H, Hogan DB, McDowell I, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005;173(5). 10.1503/cmaj.050051."},{"title3":"DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44(3):837-45."},{"title3":"Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study"},{"title3":"Liao X, Wang B, Kang Y. Novel coronavirus infection during the 2019-2020 epidemic: preparing intensive care units-the experience in Sichuan Province, China. Intensive Care Med. 2020;46(2). 10.1007/s00134-020-05954-2."},{"title3":"Xie J, Tong Z, Guan X, Du B, Qiu H, Slutsky A. Critical care crisis and some recommendations during the COVID-19 epidemic in China. Intensive Care Med. 2020. 10.1007/s00134-020-05979-7."},{"title3":"Ottestad W, Seim M, Maehlen J. COVID-19 with silent hypoxemia. Tidsskr Nor Laegeforen. 2020. 10.4045/tidsskr.20.0299."},{"title3":"NEWS2 and deterioration in COVID-19: Royal College of Physicians; 2020 [Available from: https://www.rcplondon.ac.uk/news/news2-and-deterioration-covid-19 accessed 24 April 2020."},{"title3":"Sze S, Pan D, Williams CML, Wong N, Sahota A, Bell D, et al. Letter to the editor: variability but not admission or trends in NEWS2 score predicts clinical outcome in elderly hospitalised patients with COVID-19. J Inf Secur. 2020. 10.1016/j.jinf.2020.05.063."}]}]},{"title1":"The effect of RAS blockers on the clinical characteristics of COVID-19 patients with hypertension","References":[{"title2":"World Health Organization. Coronavirus disease 2019 (COVID-19). Situation report - 45. Geneva, Switzerland: World Health Organization; March 20, 2020. Available online: https://www.who.int/docs/default-source/coronaviruse/situation-reports","References":[]},{"title2":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.","References":[{"title3":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster"},{"title3":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: adescriptivestudy"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study"},{"title3":"First case of 2019 novel coronavirus in the United States"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"Lung CT image of a confirmed case of the 2019 novel coronavirus (2019-nCoV) infected pneumonia (With differential diagnosis of the SARS)"},{"title3":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia"},{"title3":"Role of neutrophil to lymphocyte and monocyte to lymphocyte ratios in the diagnosis of bacterial infection in patients with fever"},{"title3":"Coronavirus infections-more than just the common cold"},{"title3":"The association between the neutrophil-to-lymphocyte ratio and mortality in critical illness: an observational cohort study"},{"title3":"A new coronavirus associated with human respiratory disease in China"},{"title3":"Monocyte/lymphocyte ratio as a better predictor of cardiovascular and all-cause mortality in hemodialysis patients: a prospective cohort study"},{"title3":"Ratio of neutrophil to lymphocyte counts-rapid and simple parameter of systemic inflammation and stress in critically ill"},{"title3":"Neutrophil-lymphocyte ratio as an early new marker in AIV-H7N9-infected patients: a retrospective study"}]},{"title2":"Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020. [Epub ahead of print].","References":[]},{"title2":"Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China.","References":[{"title3":"SARS: prognosis, outcome and sequelae"},{"title3":"Prevalence of diabetes in the 2009 influenza A (H1N1) and the middle east respiratory syndrome coronavirus: a systematic review and meta-analysis"},{"title3":"Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R et al (2020) A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med."},{"title3":"Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X et al (2020) Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet"},{"title3":"Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, Wang B, Xiang H, Cheng Z, Xiong Y et al (2020) Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA"},{"title3":"Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y et al (2020) Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet"},{"title3":"The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health:the latest 2019 novel coronavirus outbreak in Wuhan"},{"title3":"Guan W-J, Ni Z-Y, Hu Y, Liang W-H, Ou C-Q, He J-X, Liu L, Shan H, Lei C-L, Hui DS et al (2020) Clinical characteristics of 2019 novel coronavirus infection in China. medRxiv: 2020.02.06.20020974"},{"title3":"Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS"},{"title3":"Cardiovascular complications of severe acute respiratory syndrome"},{"title3":"Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis"},{"title3":"Preferred reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD statement"},{"title3":"Quantitative methods in the review of epidemiologic literature"},{"title3":"Meta-analysis in clinical trials"},{"title3":"The effect of statins on microalbuminuria, proteinuria, progression of kidney function, and all-cause mortality in patients with non-end stage chronic kidney disease: a meta-analysis"},{"title3":"Chang AU, Lin M, Wei L, Xie L, Zhu G, Dela Cruz CS, Sharma L (2020) Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside Wuhan, China. JAMA"},{"title3":"Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province"},{"title3":"Epidemiology, genetic recombination, and pathogenesis of coronaviruses"},{"title3":"Origin and evolution of pathogenic coronaviruses"},{"title3":"Short term outcome and risk factors for adverse clinical outcomes in adults with severe acute respiratory syndrome (SARS)"},{"title3":"Summary of the 2018 report on cardiovascular diseases in China"},{"title3":"SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS"},{"title3":"Structure of SARS coronavirus spike receptor-binding domain complexed with receptor"},{"title3":"Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, Wang W, Song H, Huang B, Zhu N et al (2020) Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet"}]},{"title2":"Structure analysis of the receptor binding of 2019-nCoV.","References":[{"title3":"A novel coronavirus outbreak of global health concern"},{"title3":"Coronaviruses: an overview of their replication and pathogenesis"},{"title3":"Structure, function, and evolution of coronavirus spike proteins"},{"title3":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus"},{"title3":"The SARS-CoV S glycoprotein: expression and functional characterization"},{"title3":"Structure of SARS coronavirus spike receptor-binding domain complexed with receptor"},{"title3":"ACE2 of the heart: from angiotensin I to angiotensin (1-7)"},{"title3":"Analysis of multimerization of the SARS coronavirus nucleocapsid protein"},{"title3":"Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human"},{"title3":"Isolation and characterization of viruses related to the SARS coronavirus from animals in southern China"},{"title3":"Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor"},{"title3":"Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2"},{"title3":"pi-Stacking interactions. Alive and well in proteins"},{"title3":"Homologous recombination within the spike glycoprotein of the newly identified coronavirus may boost cross-species transmission from snake to human"},{"title3":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis"},{"title3":"Severe acute respiratory syndrome coronavirus infection of human ciliated airway epithelia: role of ciliated cells in viral spread in the conducting airways of the lungs"},{"title3":"A cellular census of human lungs identifies novel cell states in health and in asthma"},{"title3":"Single-cell RNA sequencing identifies diverse roles of epithelial cells in idiopathic pulmonary fibrosis"},{"title3":"Severe acute respiratory syndrome: historical, epidemiologic, and clinical features"},{"title3":"Identification of a new human coronavirus"},{"title3":"Crystal structure of NL63 respiratory coronavirus receptor-binding domain complexed with its human receptor"},{"title3":"Human coronavirus NL63: a clinically important virus?"},{"title3":"Structure-based discovery of a novel angiotensin-converting enzyme 2 inhibitor"},{"title3":"Intrarenal angiotensin-converting enzyme: the old and the new"},{"title3":"Angiotensin-converting enzyme-2 (ACE2): comparative modeling of the active site, specificity requirements, and chloride dependence"}]},{"title2":"Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission.","References":[{"title3":"Transmission and evolution of the Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive genomic study"},{"title3":"Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus"},{"title3":"Evidence for a common evolutionary origin of coronavirus spike protein receptor-binding subunits"},{"title3":"Structure of SARS coronavirus spike receptor-binding domain complexed with receptor"},{"title3":"ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB"},{"title3":"Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC"},{"title3":"SWISSMODEL: an automated protein homology-modeling server"},{"title3":"GISAID: Global initiative on sharing all influenza data:from vision to reality"}]},{"title2":"Recent insights and therapeutic perspectives of angiotensin-(1-9) in the cardiovascular system.","References":[]},{"title2":"ACE2 of the heart: From angiotensin I to angiotensin (1-7).","References":[]},{"title2":"ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension.","References":[]},{"title2":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2.","References":[]},{"title2":"Renin Angiotensin system-modifying therapies are associated with improved pulmonary health.","References":[{"title3":"Lung structure and function in different stages of severe adult respiratory distress syndrome"},{"title3":"Murine models of pulmonary fibrosis"},{"title3":"Lung infections associated with cystic fibrosis"},{"title3":"Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome"},{"title3":"Outcome of patients with idiopathic pulmonary fibrosis admitted to the intensive care unit"},{"title3":"The need for new drugs against tuberculosis: obstacles, opportunities, and next steps"},{"title3":"Why drugs fail in clinical trials in pulmonary arterial hypertension, and strategies to succeed in the future"},{"title3":"Yamauchi Y, Nagase T. New anti-inflammatory drugs for COPD: is there a possibility of developing drugs that can fundamentally suppress inflammation? Chronic Obstructive Pulmonary Disease 2017:267-278."},{"title3":"Angiotensin II plays a critical role in diabetic pulmonary fibrosis most likely via activation of NADPH oxidase-mediated nitrosative damage"},{"title3":"Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling"},{"title3":"Angiotensin II-induced skeletal muscle insulin resistance mediated by NF-kappaB activation via NADPH oxidase"},{"title3":"Inflammation and the metabolic syndrome: role of angiotensin II and oxidative stress"},{"title3":"Effects of combined candesartan and ACE inhibitors on BNP, markers of inflammation and oxidative stress, and glucose regulation in patients with symptomatic heart failure"},{"title3":"Blockade of angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation"},{"title3":"Dendorfer A, Dominiak P, Schunkert H. ACE inhibitors and angiotensin II receptor antagonists. Atherosclerosis: Diet and Drugs 2005:407-442."},{"title3":"A multicenter, blinded, randomized, factorial controlled trial of doxycycline and rifampin for treatment of Alzheimer's disease: the DARAD trial"},{"title3":"Anti-inflammatory effects of statins: clinical evidence and basic mechanisms"},{"title3":"CDC grand rounds: a public health approach to detect and control hypertension"},{"title3":"Diabetes and hypertension: is there a common metabolic pathway?"},{"title3":"Impact of diabetes in patients with pulmonary hypertension"},{"title3":"Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy"},{"title3":"Ace inhibitors potently reduce vascular inflammation, results of an open proof-of-concept study in the abdominal aortic aneurysm"},{"title3":"Long-term administration of angiotensin (1-7) prevents heart and lung dysfunction in a mouse model of type 2 diabetes (db/db) by reducing oxidative stress, inflammation and pathological remodeling"}]},{"title2":"Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis.","References":[]},{"title2":"Bozkurt B, Kovacs R, Harrington B. HFSA/ACC/AHA statement addresses concerns re:using RAAS antagonists in COVID-19. March 17, 2020. Available online: https://professional.heart.org/professional/ScienceNews/UCM_505836_HFSAACCAHA-statement-addresses-concerns-re-using-RAAS-antagonists-in-COVID-19.jsp","References":[]},{"title2":"ESH Statement on COVID-19: Statement of the European Society of Hypertension (ESH) on hypertension, Renin Angiotensin System blockers and COVID-19. March 12, 2020. Available online: https://www.eshonline.org/","References":[]},{"title2":"General Office of National Health Commission. Diagnosis and treatment of novel coronavirus pneumonia (5th edition, 2020) 2020:1-12.","References":[]},{"title2":"Kenneth Schulz, David Grimes. Essential Concepts in Clinical Research - 2nd Edition Essential Concepts in Clinical Research: Randomised Controlled Trials and Observational Epidemiology (2nd ed.). Elsevier, 24th September 2018, ISBN: 9780702073946.","References":[]},{"title2":"R. 2018 Chinese Guidelines for Prevention and Treatment of Hypertension-A report of the Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension.","References":[]},{"title2":"Use of dihydropyridine calcium channel blockers in the management of hypertension in Eastern Asians: a scientific statement from the Asian Pacific Heart Association.","References":[]},{"title2":"NT-pro BNP and plasma-soluble ST2 as promising biomarkers for hypertension, hypertensive heart disease and heart failure in sub-Saharan Africa.","References":[{"title3":"The effect of left ventricular remodelling on soluble ST2 in a cohort of hypertensive subjects"},{"title3":"Relationship between left ventricular geometry and soluble ST2 in a cohort of hypertensive patients"},{"title3":"The proposed role of plasma NT pro-brain natriuretic peptide in assessing cardiac remodelling in hypertensive African subjects"},{"title3":"The causes, treatment, and outcome of acute heart failure in 1006 Africans from 9 countries"},{"title3":"Pulmonary pressures and death in heart failure: a community study"},{"title3":"BNP and NT-proBNP as prognostic markers in persons with acute decompensated heart failure: a systematic review"},{"title3":"Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function"}]},{"title2":"Angiotensin-converting enzyme inhibition is associated with reduced troponin release in non-ST-elevation acute coronary syndromes.","References":[]},{"title2":"Renin-angiotensin system inhibitors and troponin elevation in spinal surgery.","References":[]},{"title2":"The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1-7)-Mas axes in pressure overload-induced cardiac remodeling in male mice.","References":[]},{"title2":"Olmesartan attenuates pressure-overload- or post-infarction-induced cardiac remodeling in mice.","References":[{"title3":"Supplemental benefit of an angiotensin receptor blocker in hypertensive patients with stable heart failure using olmesartan (SUPPORT) trial--rationale and design"},{"title3":"A multi-center, double-blind, randomized, parallel group study to evaluate the effects of two different doses of losartan on morbidity and mortality in Chinese patients with symptomatic heart failure intolerant of angiotensin converting enzyme inhibitor treatment"},{"title3":"Effect of zofenopril and ramipril on cardiovascular mortality in patients with chronic heart failure"},{"title3":"Beneficial effects of combination of ACE inhibitor and angiotensin II type 1 receptor blocker on cardiac remodeling in rat myocardial infarction"},{"title3":"Effect of angiotensin II type 1 receptor blockade on cardiac remodeling in angiotensin II type 2 receptor null mice"},{"title3":"Combined angiotensin II receptor antagonism and angiotensin-converting enzyme inhibition further attenuates postinfarction left ventricular remodeling"},{"title3":"Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure"},{"title3":"Differential gene expression and genomic patient stratification following left ventricular assist device support"},{"title3":"Myocardial gene expression in dilated cardiomyopathy treated with beta-blocking agents"},{"title3":"AT1 receptor blockade reduces cardiac calcineurin activity in hypertensive rats"},{"title3":"Transcriptional and translational regulation of calpain in the rat heart after myocardial infarction:effects of AT and AT receptor antagonists and ACE inhibitor"},{"title3":"Expression profiling reveals distinct sets of genes altered during induction and regression of cardiac hypertrophy"},{"title3":"Protein therapeutics for cardiac regeneration after myocardial infarction"},{"title3":"Periostin as a novel factor responsible for ventricular dilation"},{"title3":"Transcriptional Reversion of Cardiac Myocyte Fate During Mammalian Cardiac Regeneration"},{"title3":"Periostin in fibrillogenesis for tissue regeneration: periostin actions inside and outside the cell"},{"title3":"Periostin is essential for cardiac healing after acute myocardial infarction"},{"title3":"The effects of periostin in a rat model of isoproterenol: mediated cardiotoxicity"},{"title3":"Left ventricular reverse remodeling after surgical therapy for aortic stenosis: correlation to Renin-Angiotensin system gene expression"},{"title3":"Expression profiling of cardiac genes in human hypertrophic cardiomyopathy: insight into the pathogenesis of phenotypes"},{"title3":"Divergent transcriptional responses to independent genetic causes of cardiac hypertrophy"},{"title3":"Developing a strategy to define the effects of insulin-like growth factor-1 on gene expression profile in cardiomyocytes"},{"title3":"Identification of genes regulated during mechanical load-induced cardiac hypertrophy"},{"title3":"Fibulin-2 is essential for angiotensin II-induced myocardial fibrosis mediated by transforming growth factor (TGF)-beta"},{"title3":"Cardiac ankyrin repeat protein is a novel marker of cardiac hypertrophy: role of M-CAT element within the promoter"},{"title3":"Chronic effects of endothelin 1 and angiotensin II on gap junctions and intercellular communication in cardiac cells"},{"title3":"Overexpression of ankyrin repeat domain 1 enhances cardiomyocyte apoptosis by promoting p53 activation and mitochondrial dysfunction in rodents"},{"title3":"Cytosolic CARP promotes angiotensin II- or pressure overload-induced cardiomyocyte hypertrophy through calcineurin accumulation"},{"title3":"Identification and characterization of a novel protein, periostin, with restricted expression to periosteum and periodontal ligament and increased expression by transforming growth factor beta"},{"title3":"Periostin (an osteoblast-specific factor) is expressed within the embryonic mouse heart during valve formation"},{"title3":"Altered patterns of gene expression in response to myocardial infarction"},{"title3":"Ablation of periostin inhibits post-infarction myocardial regeneration in neonatal mice mediated by the phosphatidylinositol 3 kinase/glycogen synthase kinase 3beta/cyclin D1 signalling pathway"},{"title3":"Clinical and experimental aspects of olmesartan medoxomil, a new angiotensin II receptor antagonist"},{"title3":"Olmesartan prevents cardiac rupture in mice with myocardial infarction by modulating growth differentiation factor 15 and p53"},{"title3":"In vitro and in vivo pharmacology of olmesartan medoxomil, an angiotensin II type AT1 receptor antagonist"},{"title3":"Potential contribution of a novel antifibrotic factor, hepatocyte growth factor, to prevention of myocardial fibrosis by angiotensin II blockade in cardiomyopathic hamsters"},{"title3":"Comparison of aldosterone synthesis in adrenal cells, effect of various AT1 receptor blockers with or without atrial natriuretic peptide"},{"title3":"Olmesartan Inhibits Cardiac Hypertrophy in Mice Overexpressing Renin Independently of Blood Pressure: Its Beneficial Effects on ACE2/Ang(1-7)/Mas Axis and NADPH Oxidase Expression"},{"title3":"Comparison of the long-term effects of candesartan and olmesartan on plasma angiotensin II and left ventricular mass index in patients with hypertension"},{"title3":"Angiotensin II increases periostin expression via Ras/p38 MAPK/CREB and ERK1/2/TGF-beta1 pathways in cardiac fibroblasts"},{"title3":"Cardiac fibrosis in mice with hypertrophic cardiomyopathy is mediated by non-myocyte proliferation and requires Tgf-beta"},{"title3":"Periostin induces proliferation of differentiated cardiomyocytes and promotes cardiac repair"},{"title3":"Stimulating myocardial regeneration with periostin Peptide in large mammals improves function post-myocardial infarction but increases myocardial fibrosis"},{"title3":"Selective Blockade of Periostin Exon 17 Preserves Cardiac Performance in Acute Myocardial Infarction"},{"title3":"Enhancement of MSC adhesion and therapeutic efficiency in ischemic heart using lentivirus delivery with periostin"},{"title3":"Targeted Ablation of Periostin-Expressing Activated Fibroblasts Prevents Adverse Cardiac Remodeling in Mice"},{"title3":"Echocardiographic assessment of LV hypertrophy and function in aortic-banded mice: necropsy validation"},{"title3":"Resveratrol improves myocardial ischemia and ischemic heart failure in mice by antagonizing the detrimental effects of fractalkine"},{"title3":"Chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade: effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesis"},{"title3":"Differential subcellular actions of ACE inhibitors and AT receptor antagonists on cardiac remodeling induced by chronic inhibition of NO synthesis in rats"},{"title3":"Myocardial Hypertrophic Preconditioning Attenuates Cardiomyocyte Hypertrophy and Slows Progression to Heart Failure Through Upregulation of S100A8/A9"},{"title3":"Acute hyperglycemia suppresses left ventricular diastolic function and inhibits autophagic flux in mice under prohypertrophic stimulation"}]},{"title2":"Ramipril and telmisartan exhibit differential effects in cardiac pressure overload-induced hypertrophy without an additional benefit of the combination of both drugs.","References":[]},{"title2":"ARB may be superior to ACEI on treatment of Marfan's syndrome by blocking TGF-beta mediated activation of ERK.","References":[]}]},{"title1":"Continued In-Hospital Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use in Hypertensive COVID-19 Patients Is Associated With Positive Clinical Outcome","References":[{"title2":"Clinical characteristics of coronavirus disease 2019 in China","References":[{"title3":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia."},{"title3":"Challenges in laboratory diagnosis of the novel coronavirus SARS-CoV-2."},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China."},{"title3":"First case of 2019 novel Coronavirus in the United States."},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study."},{"title3":"A novel coronavirus associated with severe acute respiratory syndrome."},{"title3":"A preventive and control strategy for COVID-19 infection: an experience from a Third-Tier Chinese City."},{"title3":"An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies."},{"title3":"Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China."},{"title3":"Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2."},{"title3":"COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics."},{"title3":"Transplantation of ACE2(-) mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia."},{"title3":"On the use of corticosteroids for 2019-nCoV pneumonia."},{"title3":"Comprehensive analysis of drugs to treat SARSCoV2 infection: mechanistic insights into current COVID19 therapies (Review)."},{"title3":"The role of telemedicine during the COVID-19 epidemic in China-experience from Shandong province."},{"title3":"Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial."},{"title3":"Intravenous infusion of human umbilical cord Wharton's jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia."},{"title3":"Flattening the COVID-19 curve with natural killer cell based immunotherapies."},{"title3":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster."},{"title3":"Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event."},{"title3":"Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside Wuhan, China."},{"title3":"Spatio-temporal metabolokinetics and efficacy of human placenta-derived mesenchymal stem/stromal cells on mice with refractory Crohn's-like enterocutaneous fistula."},{"title3":"High-efficient generation of VCAM-1(+) mesenchymal stem cells with multidimensional superiorities in signatures and efficacy on aplastic anaemia mice."},{"title3":"Systematic comparison of hUC-MSCs at various passages reveals the variations of signatures and therapeutic effect on acute graft-versus-host disease."},{"title3":"JNKi- and DAC-programmed mesenchymal stem/stromal cells from hESCs facilitate hematopoiesis and alleviate hind limb ischemia."},{"title3":"Identification of a novel coronavirus in patients with severe acute respiratory syndrome."},{"title3":"Studies on viral pneumonia related to novel coronavirus SARS-CoV-2, SARS-CoV, and MERS-CoV: a literature review."},{"title3":"Three emerging coronaviruses in two decades."},{"title3":"The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future."},{"title3":"Coronaviruses - drug discovery and therapeutic options."},{"title3":"The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice."},{"title3":"Acute respiratory distress syndrome: the Berlin Definition."},{"title3":"Pediatric acute respiratory distress syndrome: definition, incidence, and epidemiology: proceedings from the Pediatric Acute Lung Injury Consensus Conference."},{"title3":"Eicosanoid storm in infection and inflammation."},{"title3":"Decoding the enigma of antiviral crisis: does one target molecule regulate all?"}]},{"title2":"A novel coronavirus from patients with pneumonia in China, 2019","References":[{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study"},{"title3":"A novel coronavirus from patients with pneumonia in China, 2019"},{"title3":"Inferring the hosts of coronavirus using dual statistical models based on nucleotide composition"},{"title3":"Importation and human-to-human transmission of a novel coronavirus in Vietnam"},{"title3":"2019 novel coronavirus (2019-nCoV) outbreak: a new challenge"},{"title3":"Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan"},{"title3":"Identification of a novel coronavirus causing severe pneumonia in human: a descriptive study"},{"title3":"A new coronavirus associated with human respiratory disease in China"},{"title3":"Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China"},{"title3":"Novel Wuhan (2019-nCoV) coronavirus"},{"title3":"Severe acute respiratory syndrome coronavirus phylogeny: toward consensus"},{"title3":"Diagnosis and treatment of new coronavirus pneumonia (trial version 7) [J / OL]. Tianjin J Tradit Chin Med. 2020;1-5. http://kns.cnki.net/kcms/detail/12.1349.R.20200304.1638.006.html. Accessed 3 June 2020."},{"title3":"Clinical outcome of standardized oxygen therapy nursing strategy in COVID-19"},{"title3":"Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study"},{"title3":"Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission"},{"title3":"Angiotensin-converting enzyme 2: a functional receptor for SARS coronavirus"},{"title3":"Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection"},{"title3":"High expression of ACE2 receptor of 2019-nCoV on the epithelial cells of oral mucosa"},{"title3":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis"},{"title3":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation"},{"title3":"Organ distribution of severe acute respiratory syndrome (SARS) associated coronavirus (SARS-CoV) in SARS patients: implications for pathogenesis and virus transmission pathways"},{"title3":"Significant changes of peripheral T lymphocyte subsets in patients with severe acute respiratory syndrome"},{"title3":"Overlapping and discrete aspects of the pathology and pathogenesis of the emerging human pathogenic coronaviruses SARS-CoV, MERS-CoV, and 2019-nCoV"},{"title3":"Lactate dehydrogenase and C-reactive protein as predictors of respiratory failure in CoVID-19 patients"},{"title3":"Lactate dehydrogenase, an independent risk factor of severe COVID-19 patients: a retrospective and observational study"},{"title3":"C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early"},{"title3":"Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients in fever clinic: a retrospective case-control study"},{"title3":"Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China"},{"title3":"Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)"},{"title3":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study"},{"title3":"Human ipsc-derived cardiomyocytes are susceptible to Sars-Cov-2 infection"},{"title3":"Cardiovascular complications in COVID-19"},{"title3":"COVID-19 pandemic and troponin: indirect myocardial injury, myocardial inflammation or myocarditis?"},{"title3":"Endothelial cell infection and endotheliitis in COVID-19"}]},{"title2":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study","References":[{"title3":"Outbreak of pneumonia of unknown etiology in Wuhan China: the mystery and the miracle"},{"title3":"The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - the latest 2019 novel coronavirus outbreak in Wuhan, China"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"Clinical management of severe acute respiratory infection when Novel coronavirus (nCoV) infection is suspected: interim guidance"},{"title3":"MERS, SARS and other coronaviruses as causes of pneumonia"},{"title3":"Identification of a novel coronavirus in patients with severe acute respiratory syndrome"},{"title3":"Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia"},{"title3":"Clinical features predicting mortality risk in patients with viral pneumonia: the MuLBSTA score"},{"title3":"Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus"},{"title3":"Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human"},{"title3":"Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation"},{"title3":"Evidence for camel-to-human transmission of MERS coronavirus"},{"title3":"Surveillance of bat coronaviruses in Kenya identifies relatives of human coronaviruses NL63 and 229E and their recombination history"},{"title3":"Origin and evolution of pathogenic coronaviruses"},{"title3":"Fatal swine acute diarrhoea syndrome caused by an HKU2-related coronavirus of bat origin"},{"title3":"Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for the risk of human transmission"},{"title3":"Wuhan coronavirus has strong ability to infect humans. Press release"},{"title3":"From SARS to MERS, thrusting coronaviruses into the spotlight"},{"title3":"Prevalence of comorbidities in the Middle East respiratory syndrome coronavirus (MERS-CoV): a systematic review and meta-analysis"},{"title3":"Sex-based differences in susceptibility to severe acute respiratory syndrome coronavirus infection"},{"title3":"Sexual dimorphism in innate immunity"},{"title3":"Pathophysiology and burden of infection in patients with diabetes mellitus and peripheral vascular disease: focus on skin and soft-tissue infections"},{"title3":"Clinical findings in 111 cases of influenza A (H7N9) virus infection"},{"title3":"Clinical features of three avian influenza H7N9 virus-infected patients in Shanghai"},{"title3":"T-cell immunity of SARS-CoV: implications for vaccine development against MERS-CoV"}]},{"title2":"Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)","References":[{"title3":"Outbreak of pneumonia of unknown etiology in Wuhan, China: the mystery and the miracle"},{"title3":"The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health: the latest 2019 novel coronavirus outbreak in Wuhan, China"},{"title3":"Coronavirus infections: more than just the common cold"},{"title3":"Wuhan Municipal Health Commission. Report of clustering pneumonia of unknown etiology in Wuhan City. Published December 31, 2019. Accessed January 31, 2020. http://wjw.wuhan.gov.cn/front/web/showDetail/2019123108989"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China"},{"title3":" Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. Published March 13, 2020. Accessed January 28, 2020. https://www.who.int/publications-detail/clinical-management-of-severe-acute-respiratory-infection-when-novel-coronavirus-(ncov)-infection-is-suspected"},{"title3":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects."},{"title3":"Acute respiratory distress syndrome: the Berlin Definition"},{"title3":"Characteristics of and important lessons from the coronavirus disease 2019 (covid-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention"},{"title3":"SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS"},{"title3":"A Novel coronavirus from patients with pneumonia in China, 2019"},{"title3":"Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission"},{"title3":"Impact of angiotensin-converting enzyme inhibitors and statins on viral pneumonia"},{"title3":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury"}]},{"title2":"Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy","References":[]},{"title2":"Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area","References":[]},{"title2":"Upregulation of angiotensin converting enzyme 2 by shear stress reduced inflammation and proliferation in vascular endothelial cells","References":[]},{"title2":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2","References":[]},{"title2":"Cell type-specific expression of the putative SARS-CoV-2 receptor ACE2 in human hearts","References":[{"title3":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury"},{"title3":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor"},{"title3":"ACEH/ACE2 is a novel mammalian metallocarboxypeptidase and a homologue of angiotensin-converting enzyme insensitive to ACE inhibitors"},{"title3":"Role of the ACE2/angiotensin 1-7 axis of the renin-angiotensin system in heart failure"},{"title3":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis"},{"title3":"SARS-CoV-2: a potential novel etiology of fulminant myocarditis"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State"},{"title3":"Renin-angiotensin system in human coronavirus pathogenesis"}]},{"title2":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","References":[{"title3":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor"},{"title3":"Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2"},{"title3":"A pneumonia outbreak associated with a new coronavirus of probable bat origin"},{"title3":"Organ-protective effect of angiotensin-converting enzyme 2 and its effect on the prognosis of COVID-19"},{"title3":"Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors"},{"title3":"Relationship between angiotensin-converting enzyme insertion/deletion gene polymorphism and prostate cancer susceptibility"},{"title3":"Cell entry mechanisms of SARS-CoV-2"},{"title3":"Tissue ACE phenotyping in prostate cancer"},{"title3":"Effects of the angiotensin-I-converting enzyme inhibitor perindopril on tumor growth and angiogenesis in head and neck squamous cell carcinoma cells"},{"title3":"Clinical characteristics and results of semen tests among men with coronavirus disease 2019"},{"title3":"Role of proprotein convertases in prostate cancer progression"},{"title3":"Expression of ACE2, the SARS-CoV-2 receptor, and TMPRSS2 in prostate epithelial cells"},{"title3":"Inflammation-induced oxidative stress mediates gene fusion formation in prostate cancer"},{"title3":"Androgens and androgen receptor signaling in prostate tumorigenesis"},{"title3":"Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2"},{"title3":"The trinity of COVID-19: immunity, inflammation and intervention"},{"title3":"Epigenetic impact of infection on carcinogenesis: mechanisms and applications"},{"title3":"Prostate cancer and inflammation: the evidence"}]},{"title2":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?","References":[{"title3":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study"},{"title3":"Clinical characteristics of coronavirus disease 2019 in China"},{"title3":"Clinical characteristics of 140 patients infected by SARS-CoV-2 in Wuhan, China"},{"title3":"Receptor recognition by novel coronavirus from Wuhan: an analysis based on decade-long structural studies of SARS"},{"title3":"The vasoprotective axes of the renin-angiotensin system: physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases"}]},{"title2":"Hypertension prevalence in human coronavirus disease: the role of ACE system in infection spread and severity","References":[{"title3":"Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19"},{"title3":"China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China"},{"title3":"2018 ESC/ESH Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Cardiology and the European Society of Hypertension"},{"title3":"Associations of ACE gene insertion/deletion polymorphism, ACE activity, and ACE mRNA expression with hypertension in a Chinese population"},{"title3":"COVID-19 and African Americans"},{"title3":"Bradykinin stimulates prostaglandin E2 release in human skeletal muscular fibroblasts"},{"title3":"Pohlmann SSARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor"},{"title3":"ACE2 the Janus-faced protein - from cardiovascular protection to severe acute respiratory syndrome-coronavirus and COVID-19"}]},{"title2":"Antihypertensive treatment with ACEI/ARB of patients with COVID-19 complicated by hypertension","References":[{"title3":"The novel coronavirus: a bird's eye view"},{"title3":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding"},{"title3":"Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan"},{"title3":"Return of the coronavirus: 2019-nCoV"},{"title3":"Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody"},{"title3":"Pharmacologic modulation of ACE2 expression"},{"title3":"A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase"},{"title3":"Age- and gender-related difference of ACE2 expression in rat lung"},{"title3":"Distribution of angiotensin-(1-7) and ACE2 in human placentas of normal and pathological pregnancies"},{"title3":"A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9"},{"title3":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis"},{"title3":"Binding of SARS coronavirus to its receptor damages islets and causes acute diabetes"},{"title3":"RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak"},{"title3":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2"}]},{"title2":"COVID-19 and heart failure: from infection to inflammation and angiotensin II stimulation. Searching for evidence from a new disease","References":[{"title3":"The species severe acute respiratory syndrome-related coronavirus: classifying 2019-nCoV and naming it SARS-CoV-2"},{"title3":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding"},{"title3":"A pneumonia outbreak associated with a new coronavirus of probable bat origin"},{"title3":"COVID-19 and the cardiovascular system"},{"title3":"Potential effects of coronaviruses on the cardiovascular system: a review"},{"title3":"Coronavirus disease 2019 (COVID-19) and cardiovascular disease"},{"title3":"The science underlying COVID-19: implications for the cardiovascular system"},{"title3":"Coronaviruses and the cardiovascular system: acute and long-term implications"},{"title3":"Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China"},{"title3":"Prevalence of comorbidities and its effects in coronavirus disease 2019 patients: a systematic review and meta-analysis"},{"title3":"Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State"},{"title3":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China"},{"title3":"Covid-19 in critically ill patients in the Seattle region - case series"},{"title3":"Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province"},{"title3":"Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China"},{"title3":"Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China"},{"title3":"Characteristics and outcomes of patients hospitalized for COVID-19 and cardiac disease in Northern Italy"},{"title3":"Clinical characteristics of coronavirus disease 2019 in China"},{"title3":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study"},{"title3":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"Renin-angiotensin-aldosterone system inhibitors and risk of Covid-19"},{"title3":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention"},{"title3":"Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China"},{"title3":"Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19)"},{"title3":"Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study"},{"title3":"Renin-angiotensin-aldosterone system blockers and the risk of Covid-19"},{"title3":"Acute myocardial injury is common in patients with covid-19 and impairs their prognosis"},{"title3":"Cardiac troponin I in patients with coronavirus disease 2019 (COVID-19): evidence from a meta-analysis"},{"title3":"End-stage heart failure with COVID-19: strong evidence of myocardial injury by 2019-nCoV"},{"title3":"Cardiac involvement in a patient with coronavirus disease 2019 (COVID-19)"},{"title3":"Myocardial localization of coronavirus in COVID-19 cardiogenic shock"},{"title3":"First case of COVID-19 complicated with fulminant myocarditis: a case report and insights"},{"title3":"Cardiovascular complications of severe acute respiratory syndrome"},{"title3":"An experimental model for dilated cardiomyopathy after rabbit coronavirus infection"},{"title3":"COVID-19-related myocarditis in a 21-year-old female patient"},{"title3":"Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection"},{"title3":"Pathological findings of COVID-19 associated with acute respiratory distress syndrome"},{"title3":"Does SARS-CoV-2 cause viral myocarditis in COVID-19 patients?"},{"title3":"Acute myocardial injury, MINOCA, or myocarditis? Improving characterization of coronavirus-associated myocardial involvement"},{"title3":"COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options"},{"title3":"Fatal severe acute respiratory syndrome is associated with multiorgan involvement by coronavirus"},{"title3":"Endothelial cell infection and endotheliitis in COVID-19"},{"title3":"The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2"},{"title3":"Influenza epidemics and acute respiratory disease activity are associated with a surge in autopsy-confirmed coronary heart disease death: results from 8 years of autopsies in 34,892 subjects"},{"title3":"Association between hospitalization for pneumonia and subsequent risk of cardiovascular disease"},{"title3":"Cardiovascular complications and short-term mortality risk in community-acquired pneumonia"},{"title3":"Prevalence and significance of coagulation abnormalities in community-acquired pneumonia"},{"title3":"Nox2 up-regulation is associated with an enhanced risk of atrial fibrillation in patients with pneumonia"},{"title3":"Left ventricular performance in patients with severe acute respiratory syndrome: a 30-day echocardiographic follow-up study"},{"title3":"Mechanisms of cardiac and renal dysfunction in patients dying of sepsis"},{"title3":"Incidence of thrombotic complications in critically ill ICU patients with COVID-19"},{"title3":"COVID-19: consider cytokine storm syndromes and immunosuppression"},{"title3":"The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF study"},{"title3":"Treating oxidative stress in heart failure: past, present and future"},{"title3":"Harnessing CAR T-cell insights to develop treatments for hyperinflammatory responses in patients with COVID-19"},{"title3":"Description and proposed management of the acute COVID-19 cardiovascular syndrome"},{"title3":"Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed"},{"title3":"Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2"},{"title3":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis"},{"title3":"Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19"},{"title3":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor"},{"title3":"SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS"},{"title3":"Structural basis of receptor recognition by SARS-CoV-2"},{"title3":"Modulation of TNF-alpha-converting enzyme by the spike protein of SARS-CoV and ACE2 induces TNF-alpha production and facilitates viral entry"},{"title3":"Endocytosis of the receptor-binding domain of SARS-CoV spike protein together with virus receptor ACE2"},{"title3":"A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9"},{"title3":"Role of the ACE2/angiotensin 1-7 axis of the renin-angiotensin system in heart failure"},{"title3":"ACE inhibition, ACE2 and angiotensin-(1-7) axis in kidney and cardiac inflammation and fibrosis"},{"title3":"COVID-19, ACE2, and the cardiovascular consequences"},{"title3":"Angiotensin-converting enzyme 2 is an essential regulator of heart function"},{"title3":"Protection from angiotensin II-induced cardiac hypertrophy and fibrosis by systemic lentiviral delivery of ACE2 in rats"},{"title3":"Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction"},{"title3":"Genetic Ace2 deficiency accentuates vascular inflammation and atherosclerosis in the ApoE knockout mouse"},{"title3":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2"},{"title3":"Increased angiotensin-(1-7)-forming activity in failing human heart ventricles: evidence for upregulation of the angiotensin-converting enzyme Homologue ACE2"},{"title3":"Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors"},{"title3":"Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system"},{"title3":"Angiotensin converting enzyme 2 gene expression increased compensatory for left ventricular remodeling in patients with end-stage heart failure"},{"title3":"Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors"},{"title3":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?"},{"title3":"Drugs and the renin-angiotensin system in covid-19"},{"title3":"Coronavirus disease 2019 (COVID-19) and cardiovascular disease: a viewpoint on the potential influence of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers on onset and severity of severe acute respiratory syndrome coronavirus 2 infection"},{"title3":"Coronavirus disease 2019 (COVID-19): do angiotensin-converting enzyme inhibitors/angiotensin receptor blockers have a biphasic effect?"},{"title3":"Angiotensin-converting enzyme 2 protects from severe acute lung failure"},{"title3":"Nonpeptide antagonists of AT1 receptor for angiotensin II delay the onset of acute respiratory distress syndrome"},{"title3":"Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China"},{"title3":"Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19"}]},{"title2":"Renin-angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers","References":[{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China."},{"title3":"COVID-19 and the cardiovascular system [published ahead of print]."},{"title3":"Are patients with hypertension and diabetes mellitus at increased risk for Covid-19 infection? [published online ahead of print]."},{"title3":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus."},{"title3":"Efficient activation of the severe acute respiratory syndrome coronavirus spike protein by the transmembrane protease TMPRSS2."},{"title3":"Soluble angiotensin-converting enzyme 2: a potential approach for coronavirus infection therapy?"},{"title3":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor [published ahead of print]."},{"title3":"A pneumonia outbreak associated with a new coronavirus of probable bat origin."},{"title3":"Ang II (Angiotensin II) conversion to angiotensin-(1-7) in the circulation is POP (prolyloligopeptidase)-dependent and ACE2 (angiotensin-converting enzyme 2)-independent."},{"title3":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis."},{"title3":"Renal ACE2 expression in human kidney disease."},{"title3":"A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase."},{"title3":"Angiotensin-converting enzyme 2: enhancing the degradation of angiotensin II as a potential therapy for diabetic nephropathy."},{"title3":"Counterregulatory actions of angiotensin-(1-7)."},{"title3":"Novel therapeutic approaches targeting the renin-angiotensin system and associated peptides in hypertension and heart failure."},{"title3":"Clinical relevance and role of neuronal AT1 receptors in ADAM17-mediated ACE2 shedding in neurogenic hypertension."},{"title3":"Urine RAS components in mice and people with type 1 diabetes and chronic kidney disease."},{"title3":"Classic and nonclassic renin-angiotensin systems in the critically ill."},{"title3":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2."},{"title3":"The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1-7)-Mas axes in pressure overload-induced cardiac remodeling in male mice."},{"title3":"Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan."},{"title3":"Plasma ACE2 activity predicts mortality in aortic stenosis and is associated with severe myocardial fibrosis."},{"title3":"Angiotensin II mediates angiotensin converting enzyme type 2 internalization and degradation through an angiotensin II type I receptor-dependent mechanism."},{"title3":"Can angiotensin receptor-blocking drugs perhaps be harmful in the COVID-19 pandemic? [published ahead online]"},{"title3":"Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics [published online ahead of print]."},{"title3":"Angiotensin-converting enzyme 2 protects from severe acute lung failure."},{"title3":"Angiotensin receptor antagonists: safety and tolerability profile."},{"title3":"Therapeutic options for the 2019 novel coronavirus (2019-nCoV)."},{"title3":"Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers."}]},{"title2":"Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients","References":[{"title3":"Myocardial infarction increases ACE2 expression in rat and humans"},{"title3":"Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis"},{"title3":"Ang- (1-7) Treatment attenuates lipopolysaccharide-Induced early pulmonary fibrosis"},{"title3":"Renin-angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers"},{"title3":"Activation of angiotensin-converting enzyme 2 (ACE2) attenuates allergic airway inflammation in rat asthma model"},{"title3":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?"},{"title3":"Haemoconcentration, renal function, and post-discharge outcomes among patients hospitalized for heart failure with reduced ejection fraction: insights from the EVEREST trial"},{"title3":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus a first step in understanding SARS pathogenesis"},{"title3":"Quantitative mRNA expression profiling of ACE 2, a novel homologue of angiotensin converting enzyme"},{"title3":"TMPRSS2 and ADAM17 cleave ACE2 differentially and only proteolysis by TMPRSS2 augments entry driven by the severe acute respiratory syndrome coronavirus spike protein"},{"title3":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor"},{"title3":"Angiotensin-converting enzyme 2 protects from severe acute lung failure"},{"title3":"The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice"},{"title3":"Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors"},{"title3":"ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia"},{"title3":"Local renin-angiotensin II systems, angiotensin-converting enzyme and its homologue ACE2: their potential role in the pathogenesis of chronic obstructive pulmonary diseases, pulmonary hypertension and acute respiratory distress syndrome"},{"title3":"A pilot clinical trial of recombinant human angiotensin-converting enzyme 2 in acute respiratory distress syndrome"},{"title3":"Therapeutic strategies in an outbreak scenario to treat the novel coronavirus originating in Wuhan, China"},{"title3":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury"},{"title3":"Angiotensin-converting enzyme 2 in lung diseases"},{"title3":"The vasoprotective axes of the renin-angiotensin system: physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases"},{"title3":"Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2)"},{"title3":"Angiotensin-converting enzyme inhibitor/angiotensin II receptor blockers and pneumonia risk among stroke patients"},{"title3":"Angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis protects against lung fibrosis by inhibiting the MAPK/NF-kappaB pathway"},{"title3":"Enalapril attenuates downregulation of angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat"},{"title3":"Should COVID-19 concern nephrologists? why and to what extent? the emerging impasse of angiotensin blockade"},{"title3":"New research on possible treatments for COVID-19"},{"title3":"Post-stroke pneumonia prevention by angiotensin-converting enzyme inhibitors: results of a meta-analysis of five studies in Asians"},{"title3":"Targeting the renin-angiotensin system as novel therapeutic strategy for pulmonary diseases"},{"title3":"Renin-angiotensin-aldosterone system inhibitors in patients with COVID-19"},{"title3":"Angiotensin-converting enzyme inhibitors and bacterial pneumonia in patients with parkinson disease"},{"title3":"Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1-7) or an angiotensin II receptor antagonist"},{"title3":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation"},{"title3":"Evolution of the novel coronavirus from the ongoing wuhan outbreak and modeling of its spike protein for risk of human transmission"},{"title3":"Identification of nafamostat as a potent inhibitor of middle east respiratory syndrome coronavirus S protein-mediated membrane fusion using the split-protein-based cell-cell fusion assay"},{"title3":"Structural basis for the recognition of the 2019-nCoV by human ACE2"},{"title3":"Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury"},{"title3":"Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target"},{"title3":"COVID-19 and the cardiovascular system"},{"title3":"A pneumonia outbreak associated with a new coronavirus of probable bat origin"}]},{"title2":"Risks of ACE inhibitor and ARB usage in COVID-19: evaluating the evidence","References":[{"title3":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?"},{"title3":"Rapid response: use of angiotensin receptor blockers such as Telmisartan, Losartsan in nCoV Wuhan Corona Virus infections:novel mode of treatment. Response to the emerging novel coronavirus outbreak"},{"title3":"ACE-inhibitors, ARBs and COVID-19: what GPs need to know"},{"title3":"COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what is the evidence?"},{"title3":"Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19"},{"title3":"Antihypertensive treatment with ACEI/ARB of patients with COVID-19 complicated by hypertension"},{"title3":"Tissue-based map of the human proteome"},{"title3":"Discrepancy between intrarenal messenger RNA and protein expression of ACE and ACE2 in human diabetic nephropathy"},{"title3":"Effects of renin-angiotensin system blockade on renal angiotensin-(1-7) forming enzymes and receptors"},{"title3":"Effects of enalapril on the expression of cardiac angiotensin-converting enzyme and angiotensin-converting enzyme 2 in spontaneously hypertensive rats"},{"title3":"A simple practice guide for dose conversion between animals and human"},{"title3":"Acute respiratory distress syndrome leads to reduced ratio of ACE/ACE2 activities and is prevented by angiotensin-(1-7) or an angiotensin II receptor antagonist"},{"title3":"Angiotensin-converting enzyme inhibition attenuates lipopolysaccharide-induced lung injury by regulating the balance between angiotensin-converting enzyme and angiotensin-converting enzyme 2 and inhibiting mitogen-activated protein kinase activation"},{"title3":"Enalapril attenuates downregulation of angiotensin-converting enzyme 2 in the late phase of ventricular dysfunction in myocardial infarcted rat"},{"title3":"Differential regulation of renal angiotensin-converting enzyme (ACE) and ACE2 during ACE inhibition and dietary sodium restriction in healthy rats"},{"title3":"Losartan attenuates chronic cigarette smoke exposure-induced pulmonary arterial hypertension in rats: possible involvement of angiotensin-converting enzyme-2"},{"title3":"Chronic kidney disease: cardiac and renal angiotensin-converting enzyme (ACE) 2 expression in rats after subtotal nephrectomy and the effect of ACE inhibition"},{"title3":"Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions"},{"title3":"Enalapril protects against myocardial ischemia/reperfusion injury in a swine model of cardiac arrest and resuscitation"},{"title3":"Reduction in renal ACE2 expression in subtotal nephrectomy in rats is ameliorated with ACE inhibition"},{"title3":"Circulating ACE2 activity is increased in patients with type 1 diabetes and vascular complications"},{"title3":"Urinary angiotensin converting enzyme 2 increases in patients with type 2 diabetic mellitus"},{"title3":"Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker"},{"title3":"Circulating angiotensin-converting enzyme 2 activity in patients with chronic kidney disease without previous history of cardiovascular disease"},{"title3":"Renal ACE2 expression in human kidney disease"},{"title3":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein"},{"title3":"Structural basis of receptor recognition by SARS-CoV-2"},{"title3":"Age-and gender-related difference of ACE2 expression in rat lung"},{"title3":"Altered renal expression of angiotensin II receptors, renin receptor, and ACE-2 precede the development of renal fibrosis in aging rats"},{"title3":"The vasoprotective axes of the renin-angiotensin system: physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases"},{"title3":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study"},{"title3":"Anti-hypertensive angiotensin II receptor blockers associated to mitigation of disease severity in elderly COVID-19 patients"},{"title3":"Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19"},{"title3":"Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension"},{"title3":"Renin-angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers"},{"title3":"Alteration of cardiac ACE2/Mas expression and cardiac remodelling in rats with aortic constriction"},{"title3":"Clinical pharmacokinetics of angiotensin II (AT 1) receptor blockers in hypertension"},{"title3":"Effects of berberine on the pharmacokinetics of losartan and its metabolite EXP3174 in rats and its mechanism"},{"title3":"NDA 204308, Center for drug evaluation and research"},{"title3":"The effect of candesartan on the pharmacokinetics of enalaprilat in nephrotic rats"},{"title3":"Clinical pharmacokinetics and selective pharmacodynamics of new angiotensin converting enzyme inhibitors"},{"title3":"Peptide cotransporter 1 in intestine and organic anion transporters in kidney are targets of interaction between JBP485 and lisinopril in rats"},{"title3":"Simultaneous determination and pharmacokinetic study of losartan, losartan carboxylic acid, ramipril, ramiprilat, and hydrochlorothiazide in rat plasma by a liquid chromatography/tandem mass spectrometry method"},{"title3":"Captopril: pharmacology, metabolism, and disposition"},{"title3":"A high throughput HPLC-MS/MS method for antihypertensive drugs determination in plasma and its application on pharmacokinetic interaction study with Shuxuetong injection in rats"},{"title3":"Urinary angiotensin-converting enzyme 2 in patients with CKD"},{"title3":"Urinary angiotensin converting enzyme 2 is strongly related to urinary nephrin in type 2 diabetes patients"},{"title3":"Detection of soluble angiotensin-converting enzyme 2 in heart failure: insights into the endogenous counter-regulatory pathway of the renin-angiotensin-aldosterone system"},{"title3":"Role of circulating angiotensin converting enzyme 2 in left ventricular remodeling following myocardial infarction: a prospective controlled study"},{"title3":"Circulating ACE2 activity correlates with cardiovascular disease development"},{"title3":"Angiotensin converting enzyme 2 activity and human atrial fibrillation: increased plasma angiotensin converting enzyme 2 activity is associated with atrial fibrillation and more advanced left atrial structural remodelling"},{"title3":"Elevated plasma angiotensin converting enzyme 2 activity is an independent predictor of major adverse cardiac events in patients with obstructive coronary artery disease"}]},{"title2":"Renin-angiotensin-aldosterone system inhibitors and risk of COVID-19","References":[]},{"title2":"Effects of angiotensin II receptor blockers and ACE (angiotensin-converting enzyme) inhibitors on virus infection, inflammatory status, and clinical outcomes in patients with COVID-19 and hypertension: a single-center retrospective study","References":[]},{"title2":"Association of renin-angiotensin system inhibitors with severity or risk of death in patients with hypertension hospitalized for coronavirus disease 2019 (COVID-19) infection in Wuhan, China","References":[]},{"title2":"Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension","References":[{"title3":"Characteristics of and important Lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a Report of 72 314 cases from the Chinese Center for disease control and Prevention"},{"title3":"Intrapulmonary activation of the angiotensin-converting enzyme type 2/angiotensin 1-7/G-protein-coupled Mas receptor axis attenuates pulmonary hypertension in Ren-2 transgenic rats exposed to chronic hypoxia"},{"title3":"A pneumonia outbreak associated with a new coronavirus of probable bat origin"},{"title3":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury"},{"title3":"Recent Update of renin-angiotensin-aldosterone"},{"title3":"Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury"},{"title3":"Effect of renin-angiotensin-aldosterone system inhibitors on short-Term mortality After sepsis: a population-based aohort study"},{"title3":"Cross-talk between inflammation and angiotensin II: studies based on direct transfection of cardiomyocytes with AT1R and AT2R cDNA"},{"title3":"ACE2 exhibits protective effects against LPS-induced acute lung injury in mice by inhibiting the LPS-TLR4 pathway"},{"title3":"Beta Blocker and angiotensin-converting enzyme Inhibitor therapy Is associated with decreased Th1/Th2 cytokine ratios and inflammatory cytokine production in patients with chronic heart failure"}]},{"title2":"Association of inpatient use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19","References":[]},{"title2":"Renin-angiotensin system inhibition in cardiovascular patients at the time of COVID19: much ado for nothing? A statement of activity from the Directors of the Board and the Scientific Directors of the Italian Society of Hypertension","References":[{"title3":"Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study"},{"title3":"The epidemiology of severe acute respiratory syndrome in the 2003 Hong Kong epidemic: an analysis of all 1755 patients"},{"title3":"A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence"},{"title3":"Angiotensin-(1-7) formation in the intact human heart: in vivo dependence on angiotensin II as substrate"},{"title3":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2"},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study"},{"title3":"Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy"},{"title3":"(COVID-19) and cardiovascular disease"},{"title3":"Renin-angiotensin system blockers and the COVID-19 pandemic"},{"title3":"Is there an association between COVID-19 mortality and the renin-angiotensin System:a call for epidemiologic investigations"},{"title3":"Differential downregulation of ACE2 by the spike proteins of severe acute respiratory syndrome coronavirus and human coronavirus NL63"},{"title3":"Angiotensin-converting enzyme 2 protects from severe acute lung failure"},{"title3":"Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics"}]},{"title2":"Comorbidities in COVID-19: outcomes in hypertensive cohort and controversies with renin angiotensin system blockers","References":[{"title3":"Comorbidities in COVID-19: outcomes in hypertensivecohort and controversies with renin angiotensin system blockers"},{"title3":"ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis"},{"title3":"Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol. doi:10.1001/jamacardio.2020.1017. Published online March 27, 2020."},{"title3":"Association of inpatient use of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with mortality among patients with hypertension hospitalized with COVID-19"}]},{"title2":"Cohort of four thousand four hundred four persons under investigation for COVID-19 in a New York hospital and predictors of ICU care and ventilation","References":[{"title3":"Zu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727-733."},{"title3":"Novel coronavirus (2019-nCoV): situation report:15"},{"title3":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China"},{"title3":"China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China"},{"title3":"Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State"},{"title3":"Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study"},{"title3":"Societa Italiana di Anestesia Analgesia Rianimazione e Terapia Intensiva (SIAARTI) Airway Research Group, The European Airway Management Society. The Italian COVID-19 outbreak: experiences and recommendations from clinical practice"},{"title3":"Covid-19 in critically ill patients in the Seattle region:case series"},{"title3":"Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study"},{"title3":"Stability issues of RT-PCR testing of SARS-CoV-2 for hospitalized patients clinically diagnosed with COVID-19. J Med Virol. 2020;"},{"title3":"Looking through the retroscope: reducing bias in emergency medicine chart review studies"},{"title3":"Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med"},{"title3":"Epidemiologic features and clinical course of patients infected with SARS-CoV-2 in Singapore"},{"title3":"Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy"},{"title3":"Coronavirus disease 2019 (COVID-19) in Italy"},{"title3":"COVID-19 and Italy: what next?"},{"title3":"Clinical, laboratory and imaging features of COVID-19: a systematic review and meta-analysis"},{"title3":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study"},{"title3":"Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis"},{"title3":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study"},{"title3":"Clinical features predicting mortality risk in patients with viral pneumonia: the MuLBSTA score"}]},{"title2":"Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group","References":[]},{"title2":"Cardiac remodelling and RAS inhibition","References":[{"title3":"Chymase-dependent generation of angiotensin II from angiotensin-(1-12) in human atrial tissue"},{"title3":"Angiotensin receptor neprilysin inhibition in heart failure: mechanistic action and clinical impact"},{"title3":"Biphasic changes in thymus structure during evolving renal hypertension"},{"title3":"Lymphoid alterations and impaired T lymphocyte reactivity in experimental renal hypertension"},{"title3":"Cardiac remodeling - concepts and clinical implications: a consensus paper from an International Forum on Cardiac Remodeling"},{"title3":"A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure"},{"title3":"Cardiovascular Morbidity and mortality in the Losartan Intervention for Endpoint Reduction in Hypertension Study (LIFE): a randomised trial against atenolol"},{"title3":"Intracellular renin alters the electrical properties of the intact heart ventricle of adult Sprague-Dawley rats"},{"title3":"Translational success stories: angiotensin receptor 1 antagonists in heart failure"},{"title3":"Resolved and unresolved issues in the prevention and treatment of coronary artery disease: a workshop consensus statement"},{"title3":"Combination use of medicines from two classes of renin-angiotensin system blocking agents: risk of hyperkalemia, hypotension, and impaired renal function"},{"title3":"Addressing the theoretical and clinical advantages of combination therapy with inhibitors of the renin-angiotensin-aldosterone system: antihypertensive effects and benefits beyond BP control"},{"title3":"An evolving story of angiotensin-II-forming pathways in rodents and humans"},{"title3":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2"},{"title3":"Role of the Renin-angiotensin-aldosterone system and proinflammatory mediators in cardiovascular disease"},{"title3":"Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure"},{"title3":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial"},{"title3":"Inflammation, immunity, and hypertension"},{"title3":"Differential effects of captopril and enalapril on tissue renin-angiotensin systems in experimental heart failure"},{"title3":"Localization of the novel angiotensin peptide, angiotensin-(1-12), in heart and kidney of hypertensive and normotensive rats"},{"title3":"The origin of fibroblasts and mechanism of cardiac fibrosis"},{"title3":"Angiotensin-neprilysin inhibition versus enalapril in heart failure"},{"title3":"Increased cardiac endothelial nitric oxide synthase expression in patients taking angiotensin-converting enzyme inhibitor therapy"},{"title3":"Isolation and identification of proangiotensin-12, a possible component of the renin-angiotensin system"},{"title3":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both"},{"title3":"Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme"},{"title3":"Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats"},{"title3":"Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies"},{"title3":"Dual neurohormonal intervention in CV disease: angiotensin receptor and neprilysin inhibition"},{"title3":"Effect of the direct renin inhibitor aliskiren, the angiotensin receptor blocker losartan, or both on left ventricular mass in patients with hypertension and left ventricular hypertrophy"},{"title3":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure"},{"title3":"Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality"},{"title3":"Effects of enalapril on mortality in severe congestive heart failure. results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS)"},{"title3":"Effects of different regimens to lower blood pressure on major cardiovascular events in older and younger adults: meta-analysis of randomised trials"},{"title3":"The role of the renin-angiotensin system in the development of cardiovascular disease"},{"title3":"Prognostic significance of serial changes in left ventricular mass in essential hypertension"},{"title3":"Renin inhibition and AT1R blockade improve metabolic signaling, oxidant stress and myocardial tissue remodeling"},{"title3":"Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the Interheart Study): case-control study"},{"title3":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients"},{"title3":"The one-two punch: knocking out angiotensin II in the heart"},{"title3":"Chymase Mediates injury and mitochondrial damage in cardiomyocytes during acute ischemia/reperfusion in the dog"},{"title3":"Modulation of cardiac L-type Ca2+ current by angiotensin-(1-7): normal versus heart failure"}]},{"title2":"Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The Angiotensin-Converting-Enzyme Inhibition in Progressive Renal Insufficiency Study Group","References":[]},{"title2":"A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","References":[]},{"title2":"Angiotensin II and inflammation: the effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockade","References":[]},{"title2":"Inside the heart of COVID-19","References":[]},{"title2":"Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19","References":[{"title3":"Recent insights into 2019-nCoV: a brief but comprehensive review"},{"title3":"Clinical characteristics of coronavirus disease 2019 in China"},{"title3":"Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China"},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China"},{"title3":"A pneumonia outbreak associated with a new coronavirus of probable bat origin"},{"title3":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor"},{"title3":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein"},{"title3":"Olmesartan is an angiotensin II receptor blocker with an inhibitory effect on angiotensin-converting enzyme"},{"title3":"The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang(1-7)-Mas axes in pressure overload-induced cardiac remodeling in male mice"},{"title3":"Olmesartan attenuates the development of heart failure after experimental autoimmune myocarditis in rats through the modulation of ANG 1-7 mas receptor"},{"title3":"Cardioprotective effects of telmisartan against heart failure in rats induced by experimental autoimmune myocarditis through the modulation of angiotensin-converting enzyme-2/angiotensin 1-7/mas receptor axis"},{"title3":"Olmesartan medoxomil treatment potently improves cardiac myosininduced dilated cardiomyopathy via the modulation of ACE-2 and ANG 1-7 Mas receptor"},{"title3":"Upregulation of angiotensin-converting enzyme 2 after myocardial infarction by blockade of angiotensin II receptors"},{"title3":"Azilsartan ameliorates diabetic cardiomyopathy in young db/db mice through the modulation of ACE-2/ANG 1-7/Mas receptor cascade"},{"title3":"Role of angiotensin-converting enzyme 2/angiotensin-(1-7)/Mas axis in the hypotensive effect of azilsartan"},{"title3":"Modulation of AT-1R/MAPK cascade by an olmesartan treatment attenuates diabetic nephropathy in streptozotocin-induced diabetic mice"},{"title3":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2"},{"title3":"Localization of ACE2 in the renal vasculature: amplification by angiotensin II type 1 receptor blockade using telmisartan"},{"title3":"Telmisartan attenuates aortic hypertrophy in hypertensive rats by the modulation of ACE2 and profilin-1 expression"},{"title3":"Angiotensin II AT1 receptors regulate ACE2 and angiotensin-(1-7) expression in the aorta of spontaneously hypertensive rats"},{"title3":"Rapid response: preventing a Covid-19 pandemic: ACE inhibitors as a potential risk factor for fatal Covid-19"},{"title3":"Renin-angiotensin-aldosterone system Iinhibitors in patients with Covid-19"},{"title3":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus"},{"title3":"ACE2: from vasopeptidase to SARS virus receptor"},{"title3":"Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis"},{"title3":"The ACE2/angiotensin-(1-7)/MAS axis of the renin-angiotensin system: focus on angiotensin-(1-7)"},{"title3":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury"},{"title3":"CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus"},{"title3":"Replication-dependent downregulation of cellular angiotensin-converting enzyme 2 protein expression by human coronavirus NL63"},{"title3":"Angiotensin-converting enzyme 2 protects from severe acute lung failure"},{"title3":"Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections"},{"title3":"Angiotensin converting enzyme-2 is protective but downregulated in human and experimental lung fibrosis"},{"title3":"Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions"},{"title3":"SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19?"},{"title3":"Coronavirus disease 2019 (COVID-19) and cardiovascular disease"},{"title3":"Renin-angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to abandon renin-angiotensin system blockers"},{"title3":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study"},{"title3":"Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury"},{"title3":"SARS-CoV-2: a storm is raging"},{"title3":"Clinical characteristics and outcomes of 112 cardiovascular disease patients infected by 2019-nCoV"},{"title3":"COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. What is the evidence?"},{"title3":"The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2019)"},{"title3":"ESC Council on Hypertension. Position statement of the ESC Council on hypertension on ACE-inhibitors and angiotensin receptor blockers. 2020. https://www.escardio.org/Councils/Council-on-Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang."},{"title3":"European Society of Hypertension. Statement of the European Society of Hypertension (ESH) on hypertension, renin angiotensin system blockers and COVID-19. 2020. https://www.eshonline.org/spotlights/esh-statement-on-covid-19/."},{"title3":"Statement from the American Heart Association, the Heart Failure Society of America, and the American College of Cardiology. Patients taking ACE-i and ARBs who contract COVID-19 should continue treatment, unless otherwise advised by their physician. 2020. https://newsroom.heart.org/news/patients-taking-ace-i-and-arbs-who-contract-covid-19-should-continue-treatment-unless-otherwise-advised-by-their-physician."}]}]},{"title1":"Efficacy of ACEIs/ARBs vs CCBs on the progression of COVID?19 patients with hypertension in Wuhan: A hospital?based retrospective cohort study","References":[{"title2":"The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China","References":[{"title3":"The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - the latest 2019 novel coronavirus outbreak in Wuhan, China"}]},{"title2":"Is there an association between COVID-19 mortality and the renin-angiotensin system:a call for epidemiologic investigations","References":[{"title3":"The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China"},{"title3":"Are children less susceptible to COVID-19?"},{"title3":"Structure, function, and antigenicity of the SARS-CoV-2 Spike glycoprotein"},{"title3":"RNA based mNGS approach identifies a novel human coronavirus from two individual pneumonia cases in 2019 Wuhan outbreak"},{"title3":"Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges"},{"title3":"Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding"},{"title3":"Composition and divergence of coronavirus spike proteins and host ACE2 receptors predict potential intermediate hosts of SARS-CoV-2"},{"title3":"COVID-19 and the cardiovascular system"},{"title3":"ACE2: from vasopeptidase to SARS virus receptor"},{"title3":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus"},{"title3":"Structure analysis of the receptor binding of 2019-nCoV"},{"title3":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor"},{"title3":"Immunohistochemical, in situ hybridization, and ultrastructural localization of SARS-associated coronavirus in lung of a fatal case of severe acute respiratory syndrome in Taiwan"},{"title3":"2019 Novel coronavirus patients' clinical characteristics, discharge rate and fatality rate of meta-analysis"},{"title3":"SARS-CoV-2: a potential novel etiology of fulminant myocarditis"},{"title3":"The vasoprotective axes of the renin-angiotensin system: physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases"},{"title3":"Role of the ACE2/angiotensin 1-7 axis of the renin-angiotensin system in heart failure"},{"title3":"Circulating ACE2 in cardiovascular and kidney diseases"},{"title3":"Angiotensin-(1-7), adipokines and inflammation"},{"title3":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2"},{"title3":"Ibuprofen attenuates cardiac fibrosis in streptozotocin-induced diabetic rats"},{"title3":"The combination of ACE I/D and ACE2 G8790A polymorphisms revels susceptibility to hypertension: a genetic association study in Brazilian patients"},{"title3":"ACE2 polymorphisms associated with cardiovascular risk in Uygurs with type 2 diabetes mellitus"},{"title3":"Sex differences in renal angiotensin converting enzyme 2 (ACE2) activity are 17beta-oestradiol-dependent and sex chromosome-independent"},{"title3":"Role of circulating angiotensin converting enzyme 2 in left ventricular remodeling following myocardial infarction: a prospective controlled study"},{"title3":"Angiotensin-converting enzyme 2 protects from severe acute lung failure"},{"title3":"Angiotensin-converting enzyme 2 is an essential regulator of heart function"},{"title3":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury"},{"title3":"Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics"},{"title3":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?"}]},{"title2":"Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission","References":[{"title3":"Transmission and evolution of the Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive genomic study"},{"title3":"Discovery of a rich gene pool of bat SARS-related coronaviruses provides new insights into the origin of SARS coronavirus"},{"title3":"Evidence for a common evolutionary origin of coronavirus spike protein receptor-binding subunits"},{"title3":"Structure of SARS coronavirus spike receptor-binding domain complexed with receptor"},{"title3":"ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB"},{"title3":"Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC"},{"title3":"SWISSMODEL: an automated protein homology-modeling server"},{"title3":"GISAID: Global initiative on sharing all influenza data:from vision to reality"}]},{"title2":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2","References":[]},{"title2":"Application status of antihypertensive drugs in patients with hypertension in southwest China","References":[]},{"title2":"Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker","References":[]},{"title2":"The effects of different angiotensin II type 1 receptor blockers on the regulation of the ACE-AngII-AT1 and ACE2-Ang (1-7)-Mas axes in pressure overload-induced cardiac remodeling in male mice","References":[]},{"title2":"A language and environment for statistical computing Published online","References":[]},{"title2":"RStudio: integrated development for R","References":[]},{"title2":"Developing practical recommendations for the use of propensity scores: discussion of 'A critical appraisal of propensity score matching in the medical literature between 1996 and 2003' by Peter Austin, Statistics in Medicine","References":[]},{"title2":"Angiotensin-converting enzyme inhibitors in hypertension: to use or not to use?","References":[]},{"title2":"Clinical characteristics of coronavirus disease 2019 in China","References":[{"title3":"Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia."},{"title3":"Challenges in laboratory diagnosis of the novel coronavirus SARS-CoV-2."},{"title3":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China."},{"title3":"First case of 2019 novel Coronavirus in the United States."},{"title3":"Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study."},{"title3":"A novel coronavirus associated with severe acute respiratory syndrome."},{"title3":"A preventive and control strategy for COVID-19 infection: an experience from a Third-Tier Chinese City."},{"title3":"An emerging coronavirus causing pneumonia outbreak in Wuhan, China: calling for developing therapeutic and prophylactic strategies."},{"title3":"Measures for diagnosing and treating infections by a novel coronavirus responsible for a pneumonia outbreak originating in Wuhan, China."},{"title3":"Perspectives on therapeutic neutralizing antibodies against the Novel Coronavirus SARS-CoV-2."},{"title3":"COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics."},{"title3":"Transplantation of ACE2(-) mesenchymal stem cells improves the outcome of patients with COVID-19 pneumonia."},{"title3":"On the use of corticosteroids for 2019-nCoV pneumonia."},{"title3":"Comprehensive analysis of drugs to treat SARSCoV2 infection: mechanistic insights into current COVID19 therapies (Review)."},{"title3":"The role of telemedicine during the COVID-19 epidemic in China-experience from Shandong province."},{"title3":"Human umbilical cord-derived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial."},{"title3":"Intravenous infusion of human umbilical cord Wharton's jelly-derived mesenchymal stem cells as a potential treatment for patients with COVID-19 pneumonia."},{"title3":"Flattening the COVID-19 curve with natural killer cell based immunotherapies."},{"title3":"A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster."},{"title3":"Full-genome evolutionary analysis of the novel corona virus (2019-nCoV) rejects the hypothesis of emergence as a result of a recent recombination event."},{"title3":"Epidemiologic and clinical characteristics of novel coronavirus infections involving 13 patients outside Wuhan, China."},{"title3":"Spatio-temporal metabolokinetics and efficacy of human placenta-derived mesenchymal stem/stromal cells on mice with refractory Crohn's-like enterocutaneous fistula."},{"title3":"High-efficient generation of VCAM-1(+) mesenchymal stem cells with multidimensional superiorities in signatures and efficacy on aplastic anaemia mice."},{"title3":"Systematic comparison of hUC-MSCs at various passages reveals the variations of signatures and therapeutic effect on acute graft-versus-host disease."},{"title3":"JNKi- and DAC-programmed mesenchymal stem/stromal cells from hESCs facilitate hematopoiesis and alleviate hind limb ischemia."},{"title3":"Identification of a novel coronavirus in patients with severe acute respiratory syndrome."},{"title3":"Studies on viral pneumonia related to novel coronavirus SARS-CoV-2, SARS-CoV, and MERS-CoV: a literature review."},{"title3":"Three emerging coronaviruses in two decades."},{"title3":"The epidemic of 2019-novel-coronavirus (2019-nCoV) pneumonia and insights for emerging infectious diseases in the future."},{"title3":"Coronaviruses - drug discovery and therapeutic options."},{"title3":"The pathogenicity of SARS-CoV-2 in hACE2 transgenic mice."},{"title3":"Acute respiratory distress syndrome: the Berlin Definition."},{"title3":"Pediatric acute respiratory distress syndrome: definition, incidence, and epidemiology: proceedings from the Pediatric Acute Lung Injury Consensus Conference."},{"title3":"Eicosanoid storm in infection and inflammation."},{"title3":"Decoding the enigma of antiviral crisis: does one target molecule regulate all?"}]},{"title2":"SARS-CoV2: should inhibitors of the renin-angiotensin system be withdrawn in patients with COVID-19?","References":[{"title3":"Rapid response: re: preventing a covid-19 pandemic: ACE inhibitors as a potential risk factor for fatal Covid-19"},{"title3":"An interactive web-based dashboard to track COVID-19 in real time"},{"title3":"Clinical characteristics of coronavirus disease 2019 in China"},{"title3":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus"},{"title3":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2"},{"title3":"Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker"},{"title3":"Pathology and pathogenesis of severe acute respiratory syndrome"},{"title3":"Angiotensin-converting enzyme 2 protects from severe acute lung failure"},{"title3":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury"},{"title3":"Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics"},{"title3":"Prevalence, awareness, treatment, and control of hypertension in China: data from 1.7 million adults in a population-based screening study (China PEACE Million Persons Project)"},{"title3":"Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target"},{"title3":"2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC)Developed with the special contribution of the Heart Failure Association (HFA) of the ESC"},{"title3":"Clinical consequences of angiotensin-converting enzyme inhibitor withdrawal in chronic heart failure: a double-blind, placebo-controlled study of quinapril. The Quinapril Heart Failure Trial Investigators"},{"title3":"Initiation, continuation, or withdrawal of angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and outcomes in patients hospitalized with heart failure with reduced ejection fraction"},{"title3":"Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial"},{"title3":"2018 ESC/ESH Guidelines for the management of arterial hypertension"},{"title3":"2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC"},{"title3":"ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group"},{"title3":"Indications for ACE inhibitors in the early treatment of acute myocardial infarction: systematic overview of individual data from 100,000 patients in randomized trials. ACE Inhibitor Myocardial Infarction Collaborative Group"},{"title3":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction"},{"title3":"Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study"}]},{"title2":"ACE2 and vasoactive peptides: novel players in cardiovascular/renal remodeling and hypertension","References":[]},{"title2":"Renin angiotensin system-modifying therapies are associated with improved pulmonary health","References":[{"title3":"Lung structure and function in different stages of severe adult respiratory distress syndrome"},{"title3":"Murine models of pulmonary fibrosis"},{"title3":"Lung infections associated with cystic fibrosis"},{"title3":"Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome"},{"title3":"Outcome of patients with idiopathic pulmonary fibrosis admitted to the intensive care unit"},{"title3":"The need for new drugs against tuberculosis: obstacles, opportunities, and next steps"},{"title3":"Why drugs fail in clinical trials in pulmonary arterial hypertension, and strategies to succeed in the future"},{"title3":"Yamauchi Y, Nagase T. New anti-inflammatory drugs for COPD: is there a possibility of developing drugs that can fundamentally suppress inflammation? Chronic Obstructive Pulmonary Disease 2017:267-278."},{"title3":"Angiotensin II plays a critical role in diabetic pulmonary fibrosis most likely via activation of NADPH oxidase-mediated nitrosative damage"},{"title3":"Angiotensin II-induced insulin resistance is associated with enhanced insulin signaling"},{"title3":"Angiotensin II-induced skeletal muscle insulin resistance mediated by NF-kappaB activation via NADPH oxidase"},{"title3":"Inflammation and the metabolic syndrome: role of angiotensin II and oxidative stress"},{"title3":"Effects of combined candesartan and ACE inhibitors on BNP, markers of inflammation and oxidative stress, and glucose regulation in patients with symptomatic heart failure"},{"title3":"Blockade of angiotensin II type-1 receptor reduces oxidative stress in adipose tissue and ameliorates adipocytokine dysregulation"},{"title3":"Dendorfer A, Dominiak P, Schunkert H. ACE inhibitors and angiotensin II receptor antagonists. Atherosclerosis: Diet and Drugs 2005:407-442."},{"title3":"A multicenter, blinded, randomized, factorial controlled trial of doxycycline and rifampin for treatment of Alzheimer's disease: the DARAD trial"},{"title3":"Anti-inflammatory effects of statins: clinical evidence and basic mechanisms"},{"title3":"CDC grand rounds: a public health approach to detect and control hypertension"},{"title3":"Diabetes and hypertension: is there a common metabolic pathway?"},{"title3":"Impact of diabetes in patients with pulmonary hypertension"},{"title3":"Angiotensin II type 1 receptor blockers reduce urinary oxidative stress markers in hypertensive diabetic nephropathy"},{"title3":"Ace inhibitors potently reduce vascular inflammation, results of an open proof-of-concept study in the abdominal aortic aneurysm"},{"title3":"Long-term administration of angiotensin (1-7) prevents heart and lung dysfunction in a mouse model of type 2 diabetes (db/db) by reducing oxidative stress, inflammation and pathological remodeling"}]},{"title2":"Risk of pneumonia associated with use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers: systematic review and meta-analysis","References":[]},{"title2":"The combination of ACE I/D and ACE2 G8790A polymorphisms revels susceptibility to hypertension: a genetic association study in Brazilian patients","References":[{"title3":"Global Burden of Hypertension"},{"title3":"Cardiovascular disease: The rise of the genetic risk score"},{"title3":"Genetic screening in arterial hypertension"},{"title3":"Hereditary Determinants of Human Hypertension: Strategies in the Setting of Genetic Complexity"},{"title3":"A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase"},{"title3":"A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9"},{"title3":"ACE2, a new regulator of the renin-angiotensin system"},{"title3":"Pleiotropic effects of ACE polymorphism"},{"title3":"What's new in the renin-angiotensin system?"},{"title3":"A Modern Understanding of the Traditional and Nontraditional Biological Functions of Angiotensin-Converting Enzyme"},{"title3":"Trilogy of ACE2: A peptidase in the renin-angiotensin system, a SARS receptor, and a partner for amino acid transporters"},{"title3":"Not just angiotensinases: New roles for the angiotensin-converting enzymes"},{"title3":"Hypertension and Single Nucleotide Polymorphisms"},{"title3":"Real-time PCR for rapid genotyping of angiotensin-converting enzyme insertion/deletion polymorphism"},{"title3":"An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels"},{"title3":"Angiotensin-converting enzyme gene insertion/deletion polymorphism and essential hypertension in the Chinese population: a meta-analysis including 21 058 participants"},{"title3":"Association between the ACE I/D polymorphism and risk of ischemic stroke: An updated meta-analysis of 47,026 subjects from 105 case-control studies"},{"title3":"Meta-analysis of the ACE gene in ischaemic stroke"},{"title3":"Angiotensin converting enzyme polymorphism is associated with severity of coronary heart disease and serum lipids (total cholesterol and triglycerides levels) in Japanese patients"},{"title3":"Deletion polymorphism of the angiotensin I-converting enzyme gene is associated with serum ACE concentration and increased risk for CAD in the Japanese"},{"title3":"The Effect of ACE I/D Polymorphisms Alone and With Concomitant Risk Factors on Coronary Artery Disease"},{"title3":"Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels"},{"title3":"From gene to protein-experimental and clinical studies of ACE2 in blood pressure control and arterial hypertension"},{"title3":"No association of angiotensin-converting enzyme 2 gene (ACE2) polymorphisms with essential hypertension"},{"title3":"Case-control association study of polymorphisms in the angiotensinogen and angiotensin-converting enzyme genes and coronary artery disease and systemic artery hypertension in African-Brazilians and Caucasian-Brazilians"},{"title3":"Five polymorphisms in gene candidates for cardiovascular disease in Afro-Brazilian individuals"},{"title3":"The ACE I/D Polymorphism in US Adults: Limited Evidence of Association With Hypertension-Related Traits and Sex-Specific Effects by Race/Ethnicity"},{"title3":"Angiotensin-converting enzyme I/D polymorphism and hypertension: the Ohasama study"},{"title3":"Polymorphism of the angiotensin converting enzyme gene and blood pressure in a Japanese general population (the Shigaraki Study)"},{"title3":"ACE I/D polymorphism study in a Cuban hypertensive population"},{"title3":"Correlation of angiotensin-converting enzyme 2 gene polymorphisms with stage 2 hypertension in Han Chinese"},{"title3":"Association study of angiotensin-converting enzyme 2 gene (ACE2) polymorphisms and essential hypertension in northern Han Chinese"},{"title3":"ACE2 gene polymorphism and essential hypertension: An updated meta-analysis involving 11,051 subjects"},{"title3":"The association between angiotensinconverting enzyme 2 polymorphisms and essential hypertension risk: A metaanalysis involving 14,122 patients"},{"title3":"Polymorphisms of angiotensin-converting enzyme (ACE) and ACE2 are not associated with orthostatic blood pressure dysregulation in hypertensive patients"},{"title3":"Association of ACE, ACE2 and UTS2 Polymorphisms with Essential Hypertension in Han and Dongxiang Populations from North-western China"},{"title3":"Angiotensin converting enzyme gene I/D polymorphism, blood pressure and the renin-angiotensin system in Caucasian and Afro-Caribbean peoples"},{"title3":"Renin-Angiotensin System Genes Polymorphisms and Essential Hypertension in Burkina Faso, West Africa"},{"title3":"Lack of Association of ACE2 G8790A Gene Mutation with Essential Hypertension in the Chinese Population: A Meta-Analysis Involving 5260 Subjects"},{"title3":"Sequence variation in the human angiotensin converting enzyme"},{"title3":"Linkage and Association Analysis of Angiotensin I-Converting Enzyme (ACE)-Gene Polymorphisms with ACE Concentration and Blood Pressure"},{"title3":"The ACE2 G8790A Polymorphism: Involvement in Type 2 Diabetes Mellitus Combined with Cerebral Stroke"},{"title3":"Association study of angiotensin converting enzyme gene polymorphism with elderly diabetic hypertension and lipids levels"},{"title3":"Relationship of angiotensin converting enzyme genotype with serum triglyceride concentration in stroke patients"},{"title3":"Association of angiotensin I converting enzyme, angiotensin II type 1 receptor and angiotensin I converting enzyme 2 gene polymorphisms with the dyslipidemia in type 2 diabetic patients of Chinese Han origin"},{"title3":"Role of Ace Inhibitors In Atherosclerosis"},{"title3":"Angiotensin-converting enzyme 2 and new insights into the renin-angiotensin system"},{"title3":"Synergistic effects of gene polymorphisms of the renin-angiotensin-aldosterone system on essential hypertension in Kazakhs in Xinjiang"}]},{"title2":"ACE2 polymorphisms associated with cardiovascular risk in Uygurs with type 2 diabetes mellitus","References":[{"title3":"IDF Diabetes Atlas: global estimates for the prevalence of diabetes for 2015 and 2040"},{"title3":"Risk of non-fatal cardiovascular diseases in early-onset versus late-onset type 2 diabetes in China: a cross-sectional study"},{"title3":"Impact of age at diagnosis and duration of type 2 diabetes on mortality in Australia 1997-2011"},{"title3":"Prevalence and ethnic pattern of diabetes and prediabetes in China in 2013"},{"title3":"Status of cardiovascular health in Chinese adults"},{"title3":"Lifestyle and risk factor management in people at high risk of cardiovascular disease. A report from the European Society of Cardiology European Action on Secondary and Primary Prevention by Intervention to Reduce Events (EUROASPIRE) IV cross-sectional survey in 14 European regions"},{"title3":"Genetic predisposition to high blood pressure and lifestyle factors: associations with midlife blood pressure levels and cardiovascular events"},{"title3":"Diabetes in China: epidemiology and genetic risk factors and their clinical utility in personalized medication"},{"title3":"Polymorphisms in the gene encoding angiotensin I converting enzyme 2 and diabetic nephropathy"},{"title3":"Group UKWGS: investigation of ACE, ACE2 and AGTR1 genes for association with nephropathy in Type 1 diabetes mellitus"},{"title3":"Association of ACE2 genetic variants with blood pressure, left ventricular mass, and cardiac function in Caucasians with type 2 diabetes"},{"title3":"Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel"},{"title3":"Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?"},{"title3":"Evaluation of pleiotropic effects among common genetic loci identified for cardio-metabolic traits in a Korean population"},{"title3":"Type 2 diabetes mellitus: a review of current trends"},{"title3":"Evaluation and management of atherosclerotic carotid stenosis"},{"title3":"Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging"},{"title3":"Targeted single nucleotide polymorphism (SNP) discovery in a highly polyploid plant species using 454 sequencing"},{"title3":"Diabetes 2030: insights from yesterday, today, and future trends"},{"title3":"Cardiovascular risk assessment in patients with diabetes"},{"title3":"Metabolic risk factors of type 2 diabetes mellitus and correlated glycemic control/complications: a cross-sectional study between rural and urban uygur residents in Xinjiang Uygur Autonomous Region"},{"title3":"Diabetes device use in adults with type 1 diabetes: barriers to uptake and potential intervention targets"},{"title3":"Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010"},{"title3":"Blood pressure control in type 2 diabetic patients"},{"title3":"Predictive value of cumulative blood pressure for all-cause mortality and cardiovascular events"},{"title3":"National lipid association annual summary of clinical lipidology 2016"},{"title3":"Association of angiotensin I converting enzyme, angiotensin II type 1 receptor and angiotensin I converting enzyme 2 gene polymorphisms with the dyslipidemia in type 2 diabetic patients of Chinese Han origin"},{"title3":"Triglyceride and HDL-C dyslipidemia and risks of coronary heart disease and ischemic stroke by glycemic dysregulation status: the Strong Heart Study"},{"title3":"The genetic variation in the tenomodulin gene is associated with serum total and LDL cholesterol in a body size-dependent manner"},{"title3":"Microvasular and macrovascular complications in diabetes mellitus: distinct or continuum?"},{"title3":"Macrovascular complication phenotypes in type 2 diabetic patients"},{"title3":"Association study of ACE2 (angiotensin I-converting enzyme 2) gene polymorphisms with coronary heart disease and myocardial infarction in a Chinese Han population"},{"title3":"The ACE2 G8790A polymorphism: involvement in type 2 diabetes mellitus combined with cerebral stroke"},{"title3":"A polymorphism in ACE2 is associated with a lower risk for fatal cardiovascular events in females: the MORGAM project"},{"title3":"Variant rs10911021 that associates with coronary heart disease in type 2 diabetes, is associated with lower concentrations of circulating HDL cholesterol and large HDL particles but not with amino acids"},{"title3":"CLOCK gene variation is associated with incidence of type-2 diabetes and cardiovascular diseases in type-2 diabetic subjects: dietary modulation in the PREDIMED randomized trial"},{"title3":"National Lipid Association recommendations for patient-centered management of dyslipidemia: part 1:executive summary"},{"title3":"The association between ACE2 Gene polymorphism and the stroke recurrence in Chinese population"},{"title3":"Genetic variation in angiotensin-converting enzyme-related pathways associated with sudden cardiac arrest risk"},{"title3":"Association of polymorphisms of angiotensin I converting enzyme 2 with retinopathy in type 2 diabetes mellitus among Chinese individuals"},{"title3":"Type 1 diabetes mellitus and cardiovascular disease: a scientific statement from the American Heart Association and American Diabetes Association"},{"title3":"Angiotensin-converting enzyme 2 A1075G polymorphism is associated with survival in an acute coronary syndromes cohort"},{"title3":"Type 2 diabetes and heart failure: challenges and solutions"},{"title3":"Heart failure: the most important, preventable, and treatable cardiovascular complication of type 2 diabetes"},{"title3":"Association of angiotensin-converting enzyme 2 (ACE2) gene polymorphisms with parameters of left ventricular hypertrophy in men. Results of the MONICA Augsburg echocardiographic substudy"},{"title3":"Association between insulin resistance and the development of cardiovascular disease"},{"title3":"Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets"},{"title3":"Relationship between genetic variants of ACE2 gene and circulating levels of ACE2 and its metabolites"},{"title3":"Association between circulating levels of ACE2-Ang-(1-7)-MAS axis and ACE2 gene polymorphisms in hypertensive patients"},{"title3":"Deletion of angiotensin-converting enzyme 2 accelerates pressure overload-induced cardiac dysfunction by increasing local angiotensin II"},{"title3":"Loss of angiotensin-converting enzyme 2 leads to impaired glucose homeostasis in mice"},{"title3":"ACE and ACE2 activity in diabetic mice"}]},{"title2":"Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19","References":[]},{"title2":"2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC","References":[]},{"title2":"COVID-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what is the evidence?","References":[{"title3":"Trends in antihypertensive medication monotherapy and combination use among US adults, National Health and Nutrition Examination Survey 2005-2016"},{"title3":"Renin-angiotensin-aldosterone system inhibitors in patients with Covid-19"},{"title3":"Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019:COVID-NET, 14 States, March 1-30, 2020"},{"title3":"Risk factors for hospitalization, mechanical ventilation, or death among 10 131 US veterans with SARS-CoV-2 infection"},{"title3":"Drugs and the renin-angiotensin system in covid-19"},{"title3":"Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?"},{"title3":"Renin-angiotensin-aldosterone system inhibitors and COVID-19 infection or hospitalization: a cohort study"},{"title3":"Risk factors associated with mortality among patients with COVID-19 in intensive care units in Lombardy, Italy"},{"title3":"Renin-angiotensin-aldosterone system blockers and the risk of Covid-19"},{"title3":"Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study"},{"title3":"Association of angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use with COVID-19 diagnosis and mortality"},{"title3":"Coronavirus disease 2019 and hypertension: the role of angiotensin-converting enzyme 2 and the renin-angiotensin system"},{"title3":"Good ACE, bad ACE do battle in lung injury, SARS"},{"title3":"Kidney and lung ACE2 expression after an ACE inhibitor or an Ang II receptor blocker: implications for COVID-19"},{"title3":"Clinical and proteomic correlates of plasma ACE2 (angiotensin-converting enzyme 2) in human heart failure"},{"title3":"The expanding role of real-world evidence trials in health care decision making"},{"title3":"Real world evidence (RWE):are we (RWE) ready?"}]}]},{"title1":"Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension","References":[{"title2":"Characteristics of and important Lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: Summary of a Report of 72 314 cases from the Chinese Center for disease control and Prevention","References":[]},{"title2":"Intrapulmonary activation of the angiotensin-converting enzyme type 2/angiotensin 1-7/G-protein-coupled Mas receptor axis attenuates pulmonary hypertension in Ren-2 transgenic rats exposed to chronic hypoxia","References":[]},{"title2":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","References":[]},{"title2":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury","References":[{"title3":"A cluster of cases of severe acute respiratory syndrome in Hong Kong"},{"title3":"A major outbreak of severe acute respiratory syndrome in Hong Kong"},{"title3":"Identification of severe acute respiratory syndrome in Canada"},{"title3":"A novel coronavirus associated with severe acute respiratory syndrome"},{"title3":"Identification of a novel coronavirus in patients with severe acute respiratory syndrome"},{"title3":"Characterization of a novel coronavirus associated with severe acute respiratory syndrome"},{"title3":"The Genome sequence of the SARS-associated coronavirus"},{"title3":"Severe Acute Respiratory Syndrome (SARS) Epidemiology Working Group. WHO consensus document on the epidemiology of severe acute respiratory syndrome (SARS). (http://www.who.int/csr/sars/en/WHOconsensus.pdf, 2003)."},{"title3":"Influenza A pandemics of the 20th century with special reference to 1918: virology, pathology and epidemiology"},{"title3":"Updating the accounts: global mortality of the 1918-1920 &quot;Spanish&quot; influenza pandemic"},{"title3":"Avian influenza A (H5N1) in 10 patients in Vietnam"},{"title3":"World Health Organization. Confirmed human cases of avian influenza A (H5N1), 7 September 2004. (http://www.who.int/csr/disease/avian_influenza/country/ cases_table_2004_09_07/en/print.html, 2004)."},{"title3":"Avian influenza A virus (H7N7) associated with human conjunctivitis and a fatal case of acute respiratory distress syndrome"},{"title3":"Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus"},{"title3":"CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus"},{"title3":"Angiotensin-converting enzyme 2 is an essential regulator of heart function"},{"title3":"Prior infection and passive transfer of neutralizing antibody prevent replication of severe acute respiratory syndrome coronavirus in the respiratory tract of mice"},{"title3":"Imai, Y. et al. The SARS-coronavirus receptor angiotensin coverting enzyme 2 protects from severe acute lung failure. Nature (in the press)."},{"title3":"Chemokine receptor trafficking and viral replication"},{"title3":"pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN"},{"title3":"193-amino acid fragment of the SARS coronavirus S protein efficiently binds angiotensin-converting enzyme 2"},{"title3":"Aged BALB/c mice as a model for increased severity of severe acute respiratory syndrome in elderly humans"},{"title3":"A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9"},{"title3":"A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase"},{"title3":"Peptidyl dipeptidase A: angiotensin I-converting enzyme"},{"title3":"Cloning, expression and regulation of angiotensin II receptors"},{"title3":"Human coronaviruses-a brief review"},{"title3":"ACE1 polymorphism and progression of SARS"},{"title3":"Analysis on the SARS-CoV genome of PUMC01 isolate"},{"title3":"Comparison of lung protection strategies using conventional and high-frequency oscillatory ventilation"}]},{"title2":"Recent Update of renin-angiotensin-aldosterone","References":[{"title3":"The paradox of the low-renin state in diabetic nephropathy"},{"title3":"Cardiorenal end points in a trial of aliskiren for type 2 diabetes"},{"title3":"The intrarenalrenin-angiotensin system: from physiology to the pathobiology of hypertension and kidney disease"},{"title3":"Intrarenalangietensin II and its contribution to the genesis of chronic hypertension"},{"title3":"Liver angiotensinogen is the primary source of renal angiotension II"},{"title3":"AT1 receptor-mediated enhancement of collecting duct rennin in angiotensin II-dependent hypertensive rats"},{"title3":"A redox switch in angiotensinogen modulates angiotensin release"},{"title3":"A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9"},{"title3":"A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase"},{"title3":"Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase"},{"title3":"Angiotensin-converting enzyme 2 is an essential regulator of heart function"},{"title3":"Characteriza tion of renal angiotensin-converting enzyme 2 in diabetic nephropathy"},{"title3":"Distinct roles for ANG II and ANG-(1-7) in the regulation of angiotensin-converting enzyme 2 in rat astrocytes"},{"title3":"Angiotensin-(1-7) and the g protein-coupled receptor MAS are key players in renal inflammation"},{"title3":"ACE polymorphisms"},{"title3":"Association between renin-angiotensin-aldosterone system-related genes and blood pressure in a Korean population"},{"title3":"The ACE2 gene: Its potential as a functional candidate for cardiovascular disease"},{"title3":"Transgenic angiotensin-converting enzyme 2 overexpression in vessels of SHRSP rats reduces blood pressure and improves endothelial function"},{"title3":"Effects of captopril related to increased levels of prostacyclin and angiotensin-(1-7) in essential hypertension"},{"title3":"Structure-basedidentification of small-moleculeangiotensin-converting enzyme 2 activators as novel antihyperten-siveagents"},{"title3":"Human recombinant ACE2 reduces the progression of diabetic nephropathy"},{"title3":"AVE 0991, a nonpeptide mimic of the effect of angiotensin-(1-7) on the endothelium"},{"title3":"Discovery and validation of novel peptideagonists for G-protein-coupled receptors"}]},{"title2":"Angiotensin-converting enzyme 2 (ACE2) mediates influenza H7N9 virus-induced acute lung injury","References":[{"title3":"Lessons learnt from the human infections of avian-origin influenza A H7N9 virus: live free markets and human health"},{"title3":"Environmental connections of novel avian-origin H7N9 influenza virus infection and virus adaptation to the human"},{"title3":"Haunted with and hunting for viruses"},{"title3":"Pathogenesis and transmission of avian influenza A (H7N9) virus in ferrets and mice"},{"title3":"Clinical findings in 111 cases of influenza A (H7N9) virus infection"},{"title3":"Human infection with a novel avian-origin influenza A (H7N9) virus"},{"title3":"Origin and diversity of novel avian influenza A H7N9 viruses causing human infection: phylogenetic, structural, and coalescent analyses"},{"title3":"Human infection with H7N9 virus"},{"title3":"Biological features of novel avian influenza A (H7N9) virus"},{"title3":"Infectivity, transmission, and pathology of human-isolated H7N9 influenza virus in ferrets and pigs"},{"title3":"Angiotensin-converting enzyme 2 is an essential regulator of heart function"},{"title3":"Angiotensin-converting enzyme 2 suppresses pathological hypertrophy, myocardial fibrosis, and cardiac dysfunction"},{"title3":"Angiotensin II-mediated oxidative stress and inflammation mediate the age-dependent cardiomyopathy in ACE2 null mice"},{"title3":"ACE2, a new regulator of the renin-angiotensin system"},{"title3":"A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus-induced lung injury"},{"title3":"ACE2 links amino acid malnutrition to microbial ecology and intestinal inflammation"},{"title3":"Angiotensin-converting enzyme 2 protects from severe acute lung failure"},{"title3":"ACE2 - from the renin-angiotensin system to gut microbiota and malnutrition"},{"title3":"Angiotensin-converting enzyme 2 attenuates oxidative stress and VSMC proliferation via the JAK2/STAT3/SOCS3 and profilin-1/MAPK signaling pathways"},{"title3":"Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections"},{"title3":"Angiotensin II plasma levels are linked to disease severity and predict fatal outcomes in H7N9-infected patients"},{"title3":"Monoclonal antibody against CXCL-10/IP-10 ameliorates influenza A (H1N1) virus induced acute lung injury"},{"title3":"A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9"},{"title3":"Angiotensin converting enzyme-2 confers endothelial protection and attenuates atherosclerosis"},{"title3":"Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury"}]},{"title2":"Effect of renin-angiotensin-aldosterone system inhibitors on short-Term mortality After sepsis: a population-based aohort study","References":[]},{"title2":"Cross-talk between inflammation and angiotensin II: studies based on direct transfection of cardiomyocytes with AT1R and AT2R cDNA","References":[]},{"title2":"ACE2 exhibits protective effects against LPS-induced acute lung injury in mice by inhibiting the LPS-TLR4 pathway","References":[]},{"title2":"Beta Blocker and angiotensin-converting enzyme Inhibitor therapy Is associated with decreased Th1/Th2 cytokine ratios and inflammatory cytokine production in patients with chronic heart failure","References":[]}]}]}